BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Platelet-derived growth factor receptor expression and activation in choroid plexus tumors.

Choroid plexus tumors are intraventricular neoplasms predominantly affecting young children.

In contrast to choroid plexus papillomas, choroid plexus carcinomas progress frequently, necessitating the development of adjuvant treatment concepts.

The finding of PDGF receptor expression in choroid plexus tumors prompted us to elucidate PDGF receptor activation state using a novel method, in situ proximity ligation assay, on formalin-fixed, paraffin-embedded, archival samples of 19 choroid plexus tumors.

As assessed by in situ proximity ligation assay, the proportion of phosphorylated PDGF receptor alpha was low in choroid plexus papillomas and choroid plexus carcinomas, whereas phosphorylated PDGF receptor beta was found to be significantly higher in choroid plexus carcinomas.

In the immortalized choroid plexus epithelial cell line Z310 expressing PDGF receptor beta, PDGF-BB exhibited a time- and dose-dependent proliferative response, which was significantly attenuated by imatinib (gleevec).

In conclusion, our findings suggest that PDGF receptor beta is functionally involved in the biology of choroid plexus tumors and may represent a molecular target for therapy.

In addition, this study demonstrates the feasibility and usefulness of in situ proximity ligation assay for monitoring receptor tyrosine kinase activation in formalin-fixed, paraffin-embedded, archival tissues.

[MeSH-major] Choroid Plexus Neoplasms / metabolism. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism

[MeSH-minor] Animals. Cell Line. Cell Line, Transformed. Cell Proliferation / drug effects. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Infant. Male. Papilloma / metabolism. Papilloma / pathology. Phosphorylation / drug effects. Platelet-Derived Growth Factor / pharmacology. Rats

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]

[Cites] Comput Methods Programs Biomed. 2009 Apr;94(1):58-65 [18950895.001]

[Cites] Brain Res. 2002 Dec 27;958(2):371-80 [12470873.001]

[Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):197-204 [15207811.001]

[Cites] Mol Cancer. 2003 Jan 3;2:1 [12537587.001]

[Cites] Blood. 2004 Nov 1;104(9):2655-60 [15231574.001]

[Cites] EMBO J. 1992 Feb;11(2):543-50 [1311251.001]

[Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]

[Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]

[Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]

[Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]

[Cites] Adv Cancer Res. 2007;97:247-74 [17419949.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Mol Cell Proteomics. 2007 Sep;6(9):1500-9 [17565975.001]

[Cites] Mod Pathol. 2008 Mar;21(3):265-70 [18157090.001]

[Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]

[Cites] Nat Rev Drug Discov. 2002 Jul;1(7):493-502 [12120256.001]

(PMID = 19717644.001).

[ISSN] 1525-2191

[Journal-full-title] The American journal of pathology

[ISO-abbreviation] Am. J. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta

[Other-IDs] NLM/ PMC2751559

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model.

Despite mixed experimental data, some authors view bretylium as the drug of choice in hypothermic VF.

OBJECTIVES: To compare defibrillation rates from hypothermic VF after drug therapy with amiodarone, bretylium, and placebo.

Thirty anesthetized dogs were mechanically ventilated and instrumented to monitor coronary perfusion pressure (CPP), rectal core temperature, and electrocardiogram (ECG).

Ventricular fibrillation was induced as needed with a transthoracic AC current.

Return of spontaneous circulation (ROSC) was defined as a sustainable ECG rhythm generating a corresponding arterial pressure tracing lasting a minimum of 15 minutes.

RESULTS: CPR was adequate based on CPP > 15 mm Hg in all animals.

Mean (+/-SD) CPP was 35.3 +/- 18.8 mm Hg with an overall lower trend in the amiodarone group (p = 0.06).

[MeSH-major] Amiodarone / therapeutic use. Anti-Arrhythmia Agents / therapeutic use. Bretylium Compounds / therapeutic use. Ventricular Fibrillation / drug therapy

[MeSH-minor] Animals. Disease Models, Animal. Dogs. Hypothermia, Induced. Random Allocation

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 12615580.001).

[ISSN] 1069-6563

[Journal-full-title] Academic emergency medicine : official journal of the Society for Academic Emergency Medicine

[ISO-abbreviation] Acad Emerg Med

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Bretylium Compounds; N3RQ532IUT / Amiodarone; RZR75EQ2KJ / bretylium

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy of multi-staged surgery and adjuvant chemotherapy for successful treatment of atypical choroid plexus papilloma in an infant: case report.

A 12-month-old girl presented with a rare atypical choroid plexus papilloma manifesting as conscious disturbance and vomiting.

Only partial removal of the tumor was performed because of excessive intraoperative hemorrhage at the first surgery.

The histological diagnosis was atypical choroid plexus papilloma.

To control the intraoperative hemorrhage, embolization of the feeding artery was performed before the second surgery, and the tumor was macroscopically totally removed.

MR imaging disclosed a small residual tumor which showed relatively rapid growth.

Two months later, MR imaging showed a cystic lesion with a small nodule adjacent to the midbrain, indicating dissemination of the tumor.

The lesion was successfully treated with chemotherapy.

Atypical choroid plexus papilloma was recently defined in the classification of the World Health Organization, so clinical data based on these criteria are lacking to establish the therapeutic strategy.

Total resection of atypical choroid plexus papilloma is the most reliable treatment at present.

However, postoperative chemotherapy should be considered for recurrence or dissemination.

[MeSH-major] Brain / surgery. Lateral Ventricles / surgery. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / surgery

[MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebral Arteries / pathology. Cerebral Arteries / physiopathology. Craniotomy. Embolization, Therapeutic. Female. Humans. Infant. Intraoperative Complications / etiology. Intraoperative Complications / physiopathology. Intraoperative Complications / therapy. Lethargy / etiology. Magnetic Resonance Imaging. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neurosurgical Procedures. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / physiopathology. Postoperative Hemorrhage / therapy. Reoperation. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy. Vomiting / etiology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19855149.001).

[ISSN] 1349-8029

[Journal-full-title] Neurologia medico-chirurgica

[ISO-abbreviation] Neurol. Med. Chir. (Tokyo)

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] SNP improves cerebral hemodynamics during normotension but fails to prevent sex dependent impaired cerebral autoregulation during hypotension after brain injury.

Traumatic brain injury (TBI) is a leading cause of morbidity in children and boys are disproportionately represented.

Previous studies show that adrenomedullin, a cerebrovasodilator, prevented sex dependent impairment of autoregulation during hypotension after piglet fluid percussion brain injury (FPI).

Reductions in pial artery diameter, cortical CBF, and cerebral perfusion pressure (CPP) concomitant with elevated intracranial pressure (ICP) after FPI were greater in male compared to female piglets during normotension which was blunted by SNP.

SNP did not prevent reductions in CBF, CPP or autoregulatory index during combined hypotension and FPI in either sex.

These data suggest that therapies directed at a purely hemodynamic increase in CPP will fail to improve outcome during combined TBI and hypotension.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2010 Elsevier B.V. All rights reserved.

[Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12866-9 [10536014.001]

[Cites] J Neurotrauma. 2010 Feb;27(2):391-402 [20170313.001]

[Cites] J Cereb Blood Flow Metab. 2001 Aug;21(8):887-906 [11487724.001]

[Cites] J Neurosurg. 2002 Jan;96(1):103-8 [11794590.001]

[Cites] Anesthesiology. 2003 Feb;98(2):412-9 [12552201.001]

[Cites] Curr Opin Crit Care. 2004 Apr;10(2):120-5 [15075722.001]

[Cites] Pediatr Crit Care Med. 2004 May;5(3):257-63 [15115564.001]

[Cites] Pediatrics. 2004 Jul;114(1):79-85 [15231911.001]

[Cites] Circ Res. 1980 Jan;46(1):37-47 [7349916.001]

[Cites] J Neurosurg. 1981 Feb;54(2):170-8 [7452330.001]

[Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):145-52 [7876842.001]

[Cites] Pediatr Neurosurg. 1997 Apr;26(4):200-7 [9436831.001]

[Cites] J Head Trauma Rehabil. 2005 May-Jun;20(3):229-38 [15908823.001]

[Cites] Crit Care Med. 2005 Nov;33(11):2645-50 [16276192.001]

[Cites] Dev Neurosci. 2006;28(4-5):348-53 [16943658.001]

[Cites] Intensive Care Med. 2006 Oct;32(10):1475-84 [16896859.001]

[Cites] J Cereb Blood Flow Metab. 2007 Oct;27(10):1702-9 [17377515.001]

[Cites] Anesthesiology. 2008 Apr;108(4):588-95 [18362589.001]

[Cites] J Cereb Blood Flow Metab. 2009 Mar;29(3):524-33 [19050721.001]

[Cites] J Cereb Blood Flow Metab. 2001 Jul;21(7):779-81 [11435789.001]

(PMID = 20298682.001).

[ISSN] 1872-6240

[Journal-full-title] Brain research

[ISO-abbreviation] Brain Res.

[Language] ENG

[Grant] United States / NICHD NIH HHS / HD / HD057355-03; United States / NICHD NIH HHS / HD / R01 HD057355; United States / NICHD NIH HHS / HD / HD57355; United States / NICHD NIH HHS / HD / R01 HD057355-03

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Cardiovascular Agents; 169D1260KM / Nitroprusside; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

[Other-IDs] NLM/ NIHMS189580; NLM/ PMC2860054

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concomitant choroid plexus papillomas involving the third and fourth ventricles: A case report and review of the literature.

Choroid plexus papillomas (CPP) are histopathologically benign and rare central nervous system (CNS) neoplasms arising from the epithelium of the choroid plexus.

Third ventricular CPP are uncommon.

In this study, we present a case of a 66-year-old woman with complaints of progressive confusion, lethargy, and weakness who was found to have concomitant third and fourth ventricular masses on imaging studies.

Pathology from the biopsy and both resections was benign CPP.

Multifocal concomitant CPP is rare.

Concomitant CPPs may be secondary to mere coincidental tumor occurrence or to biologic seeding of cerebrospinal fluid (CSF) from a primary CPP despite otherwise benign histopathology.

The primary treatment for CPP is surgical resection.

Post-operative chemotherapy or radiation for CPP is of controversial benefit.

[MeSH-major] Fourth Ventricle. Papilloma, Choroid Plexus / pathology. Third Ventricle

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15963638.001).

[ISSN] 0303-8467

[Journal-full-title] Clinical neurology and neurosurgery

[ISO-abbreviation] Clin Neurol Neurosurg

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Netherlands

[Number-of-references] 21

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.

The use of cell-penetrating peptides (CPPs) as drug carriers for targeted therapy is limited by the unrestricted cellular translocation of CPPs.

The preferential induction of tumor cell death by penetratin (Antp)-directed peptides (PNC27 and PNC28), however, suggests that the CPP Antp may contribute to the preferential cytotoxicity of these peptides.

The IC(50) values of PNC27 in tumor cells were 2-3 times lower than in normal cells.

However, all three engineered peptides demonstrated similar cytotoxic effects in tumor and normal cells.

Another three chimeric peptides containing the leader peptide Antp with different mitochondria-disrupting peptides (KLA-Antp (KGA), B27-Antp (BA27), and B28-Antp (BA28)), preferentially induced apoptosis in tumor cells.

The IC(50) values of these peptides (3-10 microM) were 3-6 times lower in tumor cells than in normal cells.

In contrast, TAT-directed peptides (TAT-KLA (TK), TAT-B27 (TB27), and TAT-B28 (TB28)), were cytotoxic to both tumor and normal cells.

Furthermore, Antp-directed peptides bind chondroitin sulfate (CS), and the removal of endogenous CS reduces the cytotoxic effects of Antp-directed peptides in tumor cells.

The overexpression of CS in tumor cells is positively correlated to the cell entry and cytotoxicity of Antp- directed peptides.

These results suggest that CS overexpression in tumor cells is an important molecular portal that mediates the preferential cytotoxicity of Antp-directed peptides.

[MeSH-major] Apoptosis / drug effects. Carrier Proteins / pharmacology. Chondroitin Sulfates / pharmacology. Mitochondria / drug effects. Mitochondria / metabolism. Peptides / pharmacology

[MeSH-minor] Animals. Biological Transport / drug effects. Cell Line. Cell Line, Tumor. Cell Survival / drug effects. Female. Glycosaminoglycans / metabolism. Glycosaminoglycans / pharmacology. HeLa Cells. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Tumor Suppressor Protein p53 / pharmacology. Tumor Suppressor Protein p53 / therapeutic use. Xenograft Model Antitumor Assays

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]

[Cites] AAPS J. 2006;8(3):E532-51 [17025272.001]

[Cites] Eur J Cancer. 2007 Jun;43(9):1460-6 [17446061.001]

[Cites] Cancer Res. 2007 Jul 1;67(13):6368-75 [17616696.001]

[Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):788-93 [17635149.001]

[Cites] J Pharm Sci. 2008 Jan;97(1):144-62 [17763452.001]

[Cites] Acc Chem Res. 2008 Jan;41(1):98-107 [17705444.001]

[Cites] Bioconjug Chem. 2008 Jan;19(1):70-5 [18001077.001]

[Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):580-97 [18045730.001]

[Cites] Org Biomol Chem. 2008 Jul 7;6(13):2242-55 [18563254.001]

[Cites] In Vivo. 2008 May-Jun;22(3):385-9 [18610752.001]

[Cites] J Biol Chem. 2008 Aug 29;283(35):24274-84 [18603532.001]

[Cites] Biochim Biophys Acta. 2008 Dec;1786(2):126-38 [18440319.001]

[Cites] Ann Surg Oncol. 2008 Dec;15(12):3588-600 [18931881.001]

[Cites] Curr Drug Discov Technol. 2008 Dec;5(4):289-301 [19075609.001]

[Cites] Bioconjug Chem. 2008 Dec;19(12):2363-74 [19053306.001]

[Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):233-45 [19160015.001]

[Cites] J Biol Chem. 1999 Dec 3;274(49):34924-31 [10574967.001]

[Cites] Curr Opin Cell Biol. 2000 Aug;12(4):400-6 [10873818.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12438-43 [11606716.001]

[Cites] Mol Cell Biol. 2002 Mar;22(6):1926-35 [11865069.001]

[Cites] Cancer Res. 2002 Aug 1;62(15):4282-8 [12154030.001]

[Cites] Biochem Biophys Res Commun. 2002 Nov 1;298(3):439-49 [12413961.001]

[Cites] Oncogene. 2003 Mar 13;22(10):1431-44 [12629507.001]

[Cites] Blood. 2003 Aug 15;102(4):1307-15 [12738679.001]

[Cites] J Biol Chem. 2003 Sep 12;278(37):35109-14 [12837762.001]

[Cites] Cell Mol Life Sci. 2004 Jul;61(14):1785-94 [15241554.001]

[Cites] J Biol Chem. 1996 Nov 8;271(45):28375-81 [8910461.001]

[Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]

[Cites] Biochemistry. 1997 Feb 25;36(8):2104-11 [9047309.001]

[Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6079-84 [9600920.001]

[Cites] Nat Med. 1999 Sep;5(9):1032-8 [10470080.001]

[Cites] Int J Cancer. 2005 May 20;115(1):55-64 [15645452.001]

[Cites] Biochem J. 2005 Sep 1;390(Pt 2):407-18 [15859953.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):7840-6 [16140953.001]

[Cites] Cancer Res. 2005 Dec 1;65(23):10646-50 [16322205.001]

[Cites] Mol Cancer Ther. 2006 Jan;5(1):20-8 [16432159.001]

[Cites] Cancer Res. 2006 Apr 1;66(7):3764-72 [16585203.001]

[Cites] Int J Cancer. 2006 Oct 1;119(7):1577-85 [16688716.001]

[Cites] Mol Cancer Ther. 2006 Aug;5(8):1944-9 [16928814.001]

[Cites] J Am Chem Soc. 2007 Apr 25;129(16):4961-72 [17397150.001]

(PMID = 20484051.001).

[ISSN] 1083-351X

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycosaminoglycans; 0 / PNC-27; 0 / Peptides; 0 / Tumor Suppressor Protein p53; 0 / penetratin; 9007-28-7 / Chondroitin Sulfates

[Other-IDs] NLM/ PMC2919130

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study.

Atypical choroid plexus papilloma (APP) represents a novel intermediate-grade subtype of choroid plexus tumor (CPT), the clinical outcome of which has not been described yet.

We present the first analysis of a group of APP patients enrolled in the ongoing CPT-SIOP-2000 study of CPTs.

A worldwide registration and a randomized trial for those patients who require chemotherapy started in 2000.

After surgery, patients who had undergone complete resection were observed, whereas patients with incompletely resected or metastasized APP were treated with six chemotherapy courses (etoposide and vincristine, combined with either carboplatin or cyclophosphamide).

Of the 106 patients with a centrally confirmed CPT histology, 30 had APP, 42 CPP and 34 CPC.

APP patients were significantly younger (median = 0.7 years) than patients with CPP or CPC (both medians = 2.3 years).

Complete resection was achieved in 68 (64%) patients (79% in CPP, 63% in APP, and 47% in CPC).

Metastases were present at diagnosis in 17% of APP patients, 5% of CPP patients, and 21% of CPC patients.

All nine APP patients who received postoperative chemotherapy showed an early response after two cycles: two had complete remission, four had partial response, and three had stable disease.

In the treatment group, one patient with a metastasized tumor and incompletely resected APP died.

While APP was defined histologically, median percentages of both the Ki-67/MIB-1 proliferation marker and the p53 tumor suppressor protein increased across the three histological subtypes (from CPP to APP and then CPC), suggesting that the subtypes comprise an ordinal categorization of increasingly severe CPT tumors.

This ordering was reiterated by clinical outcome in the 92 patients treated per the study protocol, with 5-year EFS rates of 92% in 39 CPP patients, 83% in 24 APP patients, and 28% in 29 CPC patients.

APP responded favorably to chemotherapy.

The intermediate position of APP between CPP and CPC was supported by the clinical data.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / mortality. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / mortality

[MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Gadolinium. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Registries. Vincristine / administration & dosage. Young Adult

Genetic Alliance. consumer health - Choroid Plexus Papilloma.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CARBOPLATIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]

[Cites] J Neurooncol. 2000 Sep;49(3):263-8 [11212906.001]

[Cites] J Neurooncol. 2007 Dec;85(3):345-51 [17576522.001]

[Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]

[Cites] J Neurosurg. 2007 Sep;107(3 Suppl):199-202 [17918524.001]

[Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]

[Cites] J Neurooncol. 2002 Feb;56(3):241-6 [12061730.001]

[Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]

[Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]

[Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]

[Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]

[Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]

[Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]

[Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]

[Cites] J Neurooncol. 2007 Mar;82(1):69-74 [16955222.001]

[Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]

[Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]

[Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]

[Cites] Neuropathology. 2008 Apr;28(2):160-4 [18366349.001]

[Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Microsc Res Tech. 2001 Jan 1;52(1):104-11 [11135453.001]

[Cites] Neuropathology. 2009 Jun;29(3):293-8 [18627486.001]

[Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]

[Cites] Acta Neuropathol. 2002 Jan;103(1):1-10 [11837741.001]

[Cites] J Neurosurg Spine. 2006 Jun;4(6):494-6 [16776361.001]

[Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]

[Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]

[Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]

[Cites] J Neurosurg. 2004 Jun;100(6):1076-8 [15200124.001]

[Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]

[Cites] Pediatr Neurosurg. 2000 Apr;32(4):192-9 [10940770.001]

[Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]

[Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]

[Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]

[Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]

[Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):304-7 [15175083.001]

[Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]

[Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]

[Cites] Acta Neurochir (Wien). 2007 Dec;149(12):1229-36; discussion 1236-7 [17924056.001]

[Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]

[Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]

[Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]

[Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]

[Cites] Childs Nerv Syst. 1989 Oct;5(5):288-98 [2804999.001]

(PMID = 19543851.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00500890

[Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA083932

[Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; AU0V1LM3JT / Gadolinium; BG3F62OND5 / Carboplatin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND AND PURPOSE: Patients with large middle cerebral artery infarction and elevated intracranial pressure (ICP) who are undergoing invasive intensive care therapy require technical monitoring.

Furthermore, the effects of what is considered to be standard antiedema medical treatment are not fully understood.

METHODS: ICP, cerebral perfusion pressure (CPP), and partial brain tissue oxygen pressure (PbrO(2)) were continuously measured within the white matter of the frontal lobe unilaterally or bilaterally.

We analyzed the effects of antiedema drugs and looked for pattern changes in the PbrO(2) before transtentorial herniation in patients in whom this could not be prevented.

A total of 297 antiedema drug administrations were analyzed in 11 patients.

Hyper-HAES and mannitol were most often associated with an increase in CPP and PbrO(2), whereas the use of thiopental and tromethamine led to negative or contrary effects, although ICP was decreased in every case.

CONCLUSIONS: Multimodal monitoring can be used to monitor antiedema drug effects.

Furthermore, this method might help to optimize the timing of invasive therapy in space-occupying infarction.

[MeSH-major] Infarction, Middle Cerebral Artery / drug therapy. Monitoring, Physiologic / methods. Online Systems

[MeSH-minor] Brain Edema / drug therapy. Feasibility Studies. Frontal Lobe / chemistry. Frontal Lobe / physiopathology. Humans. Intracranial Hypertension. Intracranial Pressure / drug effects. Oxygen / analysis. Partial Pressure

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 11692007.001).

[ISSN] 1524-4628

[Journal-full-title] Stroke; a journal of cerebral circulation

[ISO-abbreviation] Stroke

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] S88TT14065 / Oxygen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diffuse leptomeningeal seeding from benign choroid plexus papilloma.

Choroid plexus papillomas (CPP) are rare intracranial tumours with a favourable long-term outcome after surgical excision.

Although they are histologically benign, local recurrences may occasionally occur, but leptomeningeal dissemination is exceptional.

We report an unusual example of a fourth ventricle choroid plexus papilloma with diffuse leptomeningeal seeding.

Treatment with systemic and intrathecal chemotherapy was ineffective in this patient.

We review the literature concerning leptomeningeal dissemination of benign choroid plexus papillomas.

[MeSH-major] Cerebral Ventricle Neoplasms / surgery. Fourth Ventricle / surgery. Meningeal Neoplasms / secondary. Neoplasm Seeding. Papilloma, Choroid Plexus / surgery

[MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Ki-67 Antigen / analysis. Laminectomy. Magnetic Resonance Imaging. Meninges / pathology. Reoperation. S100 Proteins / analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17924056.001).

[ISSN] 0942-0940

[Journal-full-title] Acta neurochirurgica

[ISO-abbreviation] Acta Neurochir (Wien)

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Austria

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / S100 Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intrinsic brainstem choroid plexus papilloma. Case report.

The authors report an intrinsic brainstem lesion that was diagnosed initially as a pontine cavernoma, which finally proved to be a choroid plexus papilloma.

Choroid plexus papillomas are rare tumors of the central nervous system and are usually intraventricular in location.

The occurrence of this tumor in an intraparenchymal location is extremely rare, and its occurrence within the brainstem is previously unreported.

The authors also report a trial of chemotherapy with lomustine in the management of the residual tumor.

[MeSH-major] Brain Stem Neoplasms / pathology. Choroid Plexus Neoplasms / pathology. Glioma / pathology

[MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Female. Humans. Lomustine / therapeutic use. Middle Aged

Genetic Alliance. consumer health - Choroid Plexus Papilloma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15200124.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature.

BACKGROUND: Choroid plexus papillomas are typically considered benign lesions, but histology is not always predictive of their behavior.

We present 2 cases that illustrate the wide diversity with which choroid plexus papillomas can disseminate.

CASE DESCRIPTIONS: The patient described in case 1 had a primary fourth ventricular choroid plexus papilloma that produced diffuse cystic subarachnoid and leptomeningeal lesions.

Patient 2 also had a primary fourth ventricular tumor but with subsequent suprasellar and spinal drop metastases.

Patient 2 has been treated with several modalities, including radiation therapy and chemotherapy, with slowing of symptom progression.

CONCLUSIONS: Variations of choroid plexus papilloma dissemination include intraventricular, subarachnoid, and leptomeningeal nodules or cystic lesions, and intraparenchymal locations.

There is no consensus on the most effective treatment for choroid plexus papilloma metastases; surgical resection, chemotherapy, and radiation therapy may all yield benefits.

The prognosis for patients with disseminated choroid plexus papilloma can range from prolonged stable disease and symptoms to death within months.

[MeSH-major] Choroid Plexus / pathology. Choroid Plexus / surgery. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Papilloma, Choroid Plexus / diagnosis. Papilloma, Choroid Plexus / therapy

[MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arachnoid / pathology. Arachnoid / physiopathology. Arachnoid / surgery. Disease Progression. Female. Humans. Pia Mater / pathology. Pia Mater / physiopathology. Pia Mater / surgery. Subarachnoid Space / pathology. Subarachnoid Space / physiopathology. Subarachnoid Space / surgery. Treatment Outcome

Genetic Alliance. consumer health - Choroid Plexus Papilloma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16793445.001).

[ISSN] 0090-3019

[Journal-full-title] Surgical neurology

[ISO-abbreviation] Surg Neurol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 34

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evaluation of proliferative index and cell cycle protein expression in choroid plexus tumors in children.

Choroid plexus tumors are papillary neoplasms originating from the epithelium of the choroid plexus within the cerebral ventricles.

Accordingly, we performed a clinicopathological correlation study of neoplasms arising from the choroid plexus in children using immunohistochemistry to characterize both their proliferative potential and their degree of cell cycle dysregulation when compared to non-neoplastic choroid epithelium.

Twelve children with choroid plexus papillomas (CPPs) and 11 with choroid plexus carcinomas (CPCs) were identified from the time period 1982-1997.

The outcome and survival of these children following treatment was determined from the medical record.

Immunohistochemical studies were performed on CPPs and CPCs in this patient population and on non-neoplastic choroid epithelium using antibodies to MIB-1, p53, cyclin E, retinoblastoma protein (pRB), p107, and E2F-1.

In 5 children with CPCs, tumor tissue was available for immunohistochemistry at a second surgery after cycles of chemotherapy had been given.

The mean survival for patients with CPPs was 8.5 years, and with CPCs 5.2 years with a minimum follow-up of 4 years for the group.

The expression of cell cycle markers and MIB-1 was greater in CPCs than in CPPs or normal choroid plexus.

The expression of MIB-1, p53, pRB, and E2F-1 was significantly lower in patients with CPCs after chemotherapy than before.

The MIB-1 labeling index for CPC patients who are alive and well after treatments was 15.19+/-3.2 compared to 22.63+/-3.04 for patients who have died from their disease (P<0.05).

Chemotherapy may work in part on CPCs to decrease their proliferative potential and expression of cell cycle regulatory proteins.

[MeSH-major] Cell Cycle Proteins / analysis. Choroid Plexus Neoplasms / chemistry. Choroid Plexus Neoplasms / pathology. DNA-Binding Proteins. Papilloma, Choroid Plexus / chemistry. Papilloma, Choroid Plexus / pathology

[MeSH-minor] Adolescent. Antigens, Nuclear. Cell Division. Child. Child, Preschool. Cyclin E / analysis. E2F Transcription Factors. E2F1 Transcription Factor. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Infant. Ki-67 Antigen. Male. Nuclear Proteins / analysis. Retinoblastoma Protein / analysis. Retinoblastoma-Like Protein p107. Survival Analysis. Synaptophysin / analysis. Transcription Factors / analysis. Tumor Suppressor Protein p53 / analysis

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 11837741.001).

[ISSN] 0001-6322

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / DNA-Binding Proteins; 0 / E2F Transcription Factors; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / RBL1 protein, human; 0 / Retinoblastoma Protein; 0 / Retinoblastoma-Like Protein p107; 0 / Synaptophysin; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Medical, surgical and alternative treatments for chronic pelvic pain in women: a descriptive review.

Several causes of chronic pelvic pain (CPP) are recognised, but in many women a definite diagnosis cannot be made.

Few randomised controlled trials on treatment of CPP have been conducted.

The aim of this descriptive review is to describe the management of CPP, which can focus on treating the pain itself, the underlying cause, or both.

Combination drug therapy with medications with different mechanisms of action may improve therapeutic results.

Several alternative non-invasive treatments have been proposed including exercise programmes, cognitive and behavioural medicine, physical therapy, dietary modification, massage and acupuncture.

Treatment of CPP, generally, requires acceptance of the concept of managing rather than curing symptoms.

[MeSH-major] Complementary Therapies. Pelvic Pain / drug therapy. Pelvic Pain / surgery

[MeSH-minor] Chronic Disease. Female. Humans

MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.

MedlinePlus Health Information. consumer health - Pelvic Pain.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19296329.001).

[ISSN] 1473-0766

[Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

[ISO-abbreviation] Gynecol. Endocrinol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Number-of-references] 98

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy.

OBJECTIVE: To analyze medication errors (MEs) in a multidisciplinary system with a Computerized Pharmacotherapy Process (CPP) in cancer patients.

DESIGN: A longitudinal, prospective 2-year (January 2003 -to December 2004) cohort study was made in adult patients administered antineoplastic treatment in Services of Oncology and Haematology.

MEs were identified by double cross-validation of each stage of the pharmacotherapeutic process (prescription, preparation, dispensing, administration, and follow-up) carried out by the multidisciplinary team (physician, pharmacist, nurse) with CPP assistance.

VARIABLES: Number of MEs per 1000 patient-days, percentage according to the stage of the pharmacotherapeutic process and the severity of intercepted ME (scored from 1 = no damage to the patient, to 5 = patient death).

RESULTS: A total of 1311 patients were receiving treatment, and MEs were identified in 225.

Out of a total of 13,158 patient-days, 276 MEs were detected, equivalent to 20.9 MEs per 1000 patient-days; of these, 16.8 MEs per 1000 patient-days (80%) were intercepted and did not affect any patient.

The detected ME distribution according to pharmacotherapeutic stage was: prescription 75.7%, preparation 21.0%, dispensing 1.8%, administration 1.1%, and follow-up 0.4%.

The system intercepted 98.9% of all MEs with severity >or=3 (MEs with a potential for causing patient damage).

CONCLUSIONS: The multidisciplinary system with a well-established CPP detects 20.9 MEs per 1000 patient-days and intercepts 98.8% of all MEs with a potential for causing patient damage.

[MeSH-major] Antineoplastic Agents / adverse effects. Hospitals, University / standards. Interprofessional Relations. Medication Errors / prevention & control. Medication Systems, Hospital / standards

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19617304.001).

[ISSN] 1477-092X

[Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

[ISO-abbreviation] J Oncol Pharm Pract

[Language] eng

[Publication-type] Comparative Study; Journal Article; Validation Studies

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies.

In the past 5 years, cerebral perfusion pressure (CPP) management has become the standard in the treatment of severe head injuries.

Guidelines published in 2000 suggest that CPP should be at least 70 mmHg; however, there is still debate about the optimal CPP.

The purpose of the present study was to evaluate the effectiveness of these three widely used therapies: (i) intracranial pressure (ICP) targeted;.

(ii) CPP-targeted with CPP >70 mmHg; and (iii) modified CPP-targeted (mCPP) therapy with CPP >60 mmHg.

Data, including patient age, sex, initial Glasgow Coma Scale, ICP, CPP, fluid status, amount of mannitol and vasopressor used, daily fluid intake and output, complications and clinical results, were collected from 213 patients with severe head injuries over a 12-year period.

Patients were categorized into three groups (ICP, CPP, mCPP) according to the treatment protocol used.

The mortality rate was 28.6%, 14.3% and 13.5% in the ICP, CPP, and mCPP groups, respectively.

Highest intake/output ratio, amount of vasopressor used and pulmonary complications were seen in the CPP patients.

Although CPP-targeted therapy is the most recommended therapeutic protocol, our data show that patients treated with modified CPP-target therapy with CPP >60 mmHg have better clinical outcomes and fewer complications.

[MeSH-major] Brain / blood supply. Cerebrovascular Circulation. Craniocerebral Trauma / therapy. Intracranial Hypertension / therapy

[MeSH-minor] Adolescent. Adult. Aged. Barbiturates / therapeutic use. Female. Humans. Hyperventilation. Intracranial Pressure / drug effects. Male. Middle Aged. Retrospective Studies. Treatment Outcome

MedlinePlus Health Information. consumer health - Head Injuries.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16908157.001).

[ISSN] 0967-5868

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Journal Article

[Publication-country] Scotland

[Chemical-registry-number] 0 / Barbiturates; WQ92Y2793G / barbituric acid

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Establishment of CPP-SOM integrated cDNA microarray technology].

OBJECTIVE: To get an insight into the molecular mechanisms of diseases development and targeted therapy at the transcriptome level and search for potential therapeutic targets.

METHODS: The present researchers established a cDNA microarray platform and applied component plane presentation integrated self-organizing map (CPP-SOM) to the microarray data obtained from a differentiation model, all trans retinoic acid-induced differentiation in NB4 cells.

By CPP-SOM, the researchers were able to not only well classify the regulated genes into functionally distinct categories but also depict transcriptional changes throughout the process of the development of diseases or drug treatment.

CONCLUSION: The platform has proven to be steady and reliable, and the CPP-SOM could serve as an important and good tool for analysis of microarray data.

[MeSH-minor] Cell Line, Tumor. Humans. Reverse Transcriptase Polymerase Chain Reaction

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15476161.001).

[ISSN] 1003-9406

[Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

[ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors.

BACKGROUND: Choroid plexus carcinomas (CPC) are rare brain tumors with a dismal prognosis.

Although the role of surgery has been well established, the question of whether chemotherapy improves the prognosis is still under discussion.

METHODS: We created a database of all cases of choroid plexus tumors (CPT) reported in the literature up to the year 2004 to determine prognostic factors and different therapeutic modalities.

RESULTS: Of 857 documented cases of CPT (median patient age at diagnosis, 3 years), 347 were CPC, 15 atypical choroid plexus papilloma (APP), and 495 choroid plexus papilloma (CPP).

The 104 CPC patients who received chemotherapy had a statistically better survival than those without chemotherapy (P = .0004).

When subgroups were defined by radiation treatment, chemotherapy remained beneficial in the subgroup of nonirradiated tumors (P = .0001).

The benefit of chemotherapy was also significant when the analysis was restricted to the subgroup of patients with less than completely resected CPC (2-year overall survival (OS) 54.8 +/- 7% (standard deviation (SD) vs. 24.4 +/- 7%, P < .0001) and when this subgroup was further divided into smaller subgroups.

Likewise, in a multivariate analysis, chemotherapy was highly significantly linked to better prognosis (P = .0001).

CONCLUSION: Patients with less than completely resected CPC should receive chemotherapy.

[MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Choroid Plexus Neoplasms / drug therapy

[MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Combined Modality Therapy. Databases, Bibliographic. Databases, Factual. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - Choroid Plexus Carcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurooncol. 2002 Apr;57(2):123-6 [12125972.001]

[Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]

[Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]

[Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]

[Cites] Eur J Pediatr. 1983 Mar;140(1):51-6 [6873113.001]

[Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):249-54 [10760416.001]

[Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]

[Cites] Brain Pathol. 2003 Jul;13(3):409-14 [12946029.001]

[Cites] Am J Hum Genet. 1999 Nov;65(5):1342-8 [10521299.001]

[Cites] Med Pediatr Oncol. 1994;22(4):274-8 [8107660.001]

[Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]

[Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]

[Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]

[Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]

[Cites] Histopathology. 1995 Feb;26(2):137-43 [7737660.001]

[Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]

[Cites] J Neurosurg. 1983 Sep;59(3):369-83 [6886750.001]

[Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]

[Cites] Acta Neurochir (Wien). 1998;140(6):557-63 [9755322.001]

[Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]

[Cites] Neuropediatrics. 1996 Jun;27(3):143-8 [8837074.001]

[Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]

[Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]

[Cites] Acta Oncol. 1990;29(2):241-3 [2185805.001]

[Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]

[Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]

[Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]

[Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]

[Cites] Neoplasma. 2004;51(4):306-12 [15254663.001]

[Cites] Childs Brain. 1975;1(2-3):81-115 [1081032.001]

[Cites] Childs Nerv Syst. 1999 Oct;15(10):571-7 [10550588.001]

[Cites] Neurosurgery. 1980 Apr;6(4):380-4 [7393420.001]

[Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]

[Cites] Neurol Med Chir (Tokyo). 1996 Mar;36(3):179-84 [8869156.001]

[Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]

[Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]

[Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]

[Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]

[Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]

(PMID = 17576522.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article; Meta-Analysis

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Repeated 2 Hz peripheral electrical stimulations suppress morphine-induced CPP and improve spatial memory ability in rats.

Our previous studies have shown that 2 Hz peripheral electrical stimulation (PES) can suppress morphine-induced conditioned place preference (CPP) in the rat, although the mechanisms remain unclear.

Since CPP involves the mechanism of learning and memory, it is rational to ask whether the suppressive effect of repeated 2 Hz PES on morphine-induced CPP is due to an impairment of the function of spatial learning and memory.

Rats were trained with 4 mg/kg morphine, i.p. for 4 days to establish the CPP.

Twenty-four hours after the CPP testing, they were given PES at 2 Hz once a day for 1, 3 or 5 days, followed by another CPP testing.

The results showed that (1) the morphine-induced CPP was significantly inhibited by 3 or 5 consecutive sessions, but not by single session of 2 Hz PES. (2) A test of spatial leaning and memory ability using the Morris water maze task revealed that 2 Hz PES per se exhibited a promoting, rather than a deteriorating effect on the ability of spatial memory. (3) 2 Hz PES by itself produced a moderate yet significant CPP.

The results imply that (a) a low frequency PES can produce a rewarding effect as revealed by the CPP testing, which may account, at least in part, for its suppressive effect on morphine induced CPP, (b) the suppressive effect of PES on morphine induced CPP is not due to a deteriorating effect on the ability of spatial memory.

[MeSH-major] Conditioning (Psychology) / drug effects. Electroacupuncture. Maze Learning / drug effects. Memory Disorders / therapy. Morphine Dependence / therapy. Substance Withdrawal Syndrome / therapy

[MeSH-minor] Animals. Brain / drug effects. Brain / physiopathology. Disease Models, Animal. Male. Morphine / adverse effects. Narcotics / adverse effects. Rats. Rats, Sprague-Dawley. Recovery of Function / physiology. Reward. Treatment Outcome

MedlinePlus Health Information. consumer health - Memory.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15890338.001).

[ISSN] 0014-4886

[Journal-full-title] Experimental neurology

[ISO-abbreviation] Exp. Neurol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Narcotics; 76I7G6D29C / Morphine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ICP threshold in CPP management of severe head injury patients.

BACKGROUND: Elevated intracranial pressure (ICP) is significantly associated with high mortality rate in severe head injury (SHI) patients.

METHODS: Treatment protocol in this study consisted of therapeutic maneuvers designed to maximize cerebral profusion pressure (CPP) and control ICP.

Twenty-seven patients with severe head injury and intracranial hypertension (ICP >or=20 mm Hg) were enrolled and fourteen cases were allocated to the group of ICP threshold >or=25 mm Hg.

Logistic regression identified the presence of basal cisterns on the initial computed tomography (CT) scan as a significant predictor of good outcome.

[MeSH-major] Brain / blood supply. Craniocerebral Trauma / complications. Intracranial Hypertension / etiology. Intracranial Hypertension / therapy

[MeSH-minor] Adult. Algorithms. Cerebral Hemorrhage, Traumatic / diagnosis. Cerebral Hemorrhage, Traumatic / drug therapy. Cerebral Hemorrhage, Traumatic / etiology. Combined Modality Therapy. Diuretics, Osmotic / therapeutic use. Glasgow Coma Scale. Humans. Mannitol / therapeutic use. Oxygen / therapeutic use. Prospective Studies

MedlinePlus Health Information. consumer health - Head Injuries.

Hazardous Substances Data Bank. D-MANNITOL .

Hazardous Substances Data Bank. OXYGEN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15120212.001).

[ISSN] 0090-3019

[Journal-full-title] Surgical neurology

[ISO-abbreviation] Surg Neurol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Diuretics, Osmotic; 3OWL53L36A / Mannitol; S88TT14065 / Oxygen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo.

Effects of N-methyl-D-aspartate (NMDA) receptor and Ca2+ channel antagonists on extracellular acetylcholine and choline release in the hippocampus of ethanol-withdrawn rats were investigated by in vivo microdialysis.

Either an NMDA receptor antagonist (+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) or a calcium channel antagonist amlodipine was administered, and 15 min later, an audiogenic stimulus (100 dB, 1 min) was applied to rats.

CPP (15 mg/kg) and amlodipine (20 mg/kg) reversed the decrement in acetylcholine and increment in choline release in EW rats.

[MeSH-major] Acetylcholine / metabolism. Amlodipine / pharmacology. Ethanol / adverse effects. Hippocampus / drug effects. Piperazines / pharmacology. Substance Withdrawal Syndrome / metabolism

[MeSH-minor] Acoustic Stimulation / adverse effects. Alcohol-Induced Disorders, Nervous System / drug therapy. Alcohol-Induced Disorders, Nervous System / metabolism. Alcohol-Induced Disorders, Nervous System / physiopathology. Animals. Body Weight / drug effects. Calcium Channel Blockers / pharmacology. Choline / metabolism. Disease Models, Animal. Down-Regulation / drug effects. Down-Regulation / physiology. Drug Interactions / physiology. Epilepsy, Reflex / chemically induced. Epilepsy, Reflex / drug therapy. Epilepsy, Reflex / physiopathology. Excitatory Amino Acid Agonists / pharmacology. Glutamic Acid / metabolism. Male. Microdialysis. Neural Pathways / drug effects. Neural Pathways / metabolism. Neural Pathways / physiopathology. Rats. Rats, Wistar. Seizures / chemically induced. Seizures / drug therapy. Seizures / physiopathology. Synaptic Transmission / drug effects. Synaptic Transmission / physiology

Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .

Hazardous Substances Data Bank. ETHANOL .

Hazardous Substances Data Bank. CHOLINE CHLORIDE .

Hazardous Substances Data Bank. AMLODIPINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15464861.001).

[ISSN] 0361-9230

[Journal-full-title] Brain research bulletin

[ISO-abbreviation] Brain Res. Bull.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Excitatory Amino Acid Agonists; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 1J444QC288 / Amlodipine; 3K9958V90M / Ethanol; 3KX376GY7L / Glutamic Acid; N91BDP6H0X / Choline; N9YNS0M02X / Acetylcholine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma.

A pregnant 33-year old woman developed nystagmus and cerebellar ataxia.

A tumor in the roof of the fourth ventricle was diagnosed.

The tumor was subtotally removed using microneurosurgical techniques.

The histopathological diagnosis was choroid plexus papilloma (CPP).

Twenty-one months later, the tumor recurred and was reoperated.

Histologically the tumor displayed now increased mitotic activity and pleomorphism.

Radiation therapy of the neuroaxis was performed.

Within 59 months, the CPP recurred 3 more times with neuroradiological evidence of extensive spinal seeding.

After several palliative irradiations, including 2 gamma-knife boosts, the patient was referred to chemotherapy.

The course of disease in our patient provides evidence for therapeutic efficacy of CCNU in recurrent CPP.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Lomustine / therapeutic use. Papilloma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

[MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neoplasm Seeding. Pregnancy. Reoperation

Genetic Alliance. consumer health - Choroid Plexus Papilloma.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int Rev Cytol. 1980;65:117-91 [6248480.001]

[Cites] J Comput Assist Tomogr. 1979 Aug;3(4):530-2 [457968.001]

[Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]

[Cites] J Neurosurg. 1982 May;56(5):722-7 [7069487.001]

[Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]

[Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]

[Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]

[Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]

[Cites] Surg Neurol. 1984 Nov;22(5):472-6 [6495155.001]

[Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]

[Cites] J Neurosurg. 1977 Sep;47(3):442-50 [894346.001]

[Cites] Klin Padiatr. 1995 Mar-Apr;207(2):52-8 [7752600.001]

[Cites] J Neurosurg. 1960 Nov;17:1002-27 [13768200.001]

[Cites] Brain. 1967 Mar;90(1):177-86 [6023072.001]

[Cites] Cancer. 1983 Feb 1;51(3):470-5 [6821827.001]

[Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]

[Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]

[Cites] Acta Cytol. 1985 Sep-Oct;29(5):846-9 [3863432.001]

[Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]

[Cites] Zentralbl Allg Pathol. 1959 Nov 30;100:136-42 [13818457.001]

[Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]

[Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]

(PMID = 11212906.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine

[Number-of-references] 30

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice.

The monoamine transporters are the main targets of psychostimulant drugs, including methamphetamine (METH) and cocaine.

Interestingly, the rewarding effects of cocaine are retained in dopamine transporter (DAT) knockout (KO) mice, while serotonin transporter (SERT) and DAT double KO mice do not exhibit conditioned place preference (CPP) to cocaine.

) CPP and locomotor sensitization to 1 mg/kg METH (i.p.) in C57BL/6J mice.

Fluoxetine treatment before both the conditioning and preference tests abolished METH CPP.

A two-way analysis of variance (ANOVA) revealed that METH CPP tended to be lower in mice pretreated with fluoxetine before the preference test than in control mice pretreated with saline before the preference test.

These results suggest that fluoxetine, a widely used medication for depression, may be also a useful tool for treating METH dependence.

[MeSH-major] Amphetamine-Related Disorders / drug therapy. Dopamine Agents / toxicity. Fluoxetine / therapeutic use. Methamphetamine / toxicity. Motor Activity / drug effects. Serotonin Uptake Inhibitors / therapeutic use

MedlinePlus Health Information. consumer health - Methamphetamine.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17105925.001).

[ISSN] 0077-8923

[Journal-full-title] Annals of the New York Academy of Sciences

[ISO-abbreviation] Ann. N. Y. Acad. Sci.

[Language] eng

[Grant] United States / NIDA NIH HHS / DA / R01 DA11946

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Dopamine Agents; 0 / Serotonin Uptake Inhibitors; 01K63SUP8D / Fluoxetine; 44RAL3456C / Methamphetamine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVES: The purpose of this study was to examine whether rimonabant, a cannabinoid CB1 receptor antagonist, would disrupt the consolidation and reconsolidation of methamphetamine-related reward memory, using conditioned place preference paradigm (CPP).

MATERIALS AND METHODS: Separate groups of male Kunming mice were trained to acquire methamphetamine CPP.

Vehicle or rimonabant (1 mg/kg or 3 mg/kg, i.p.) was given at different time points: immediately after each CPP training session (consolidation), 30 min before the reactivation of CPP (retrieval), or immediately after the reactivation of CPP (reconsolidation).

Methamphetamine CPP was retested 24 h and 1 and 2 weeks after rimonabant administration.

RESULTS: Rimonabant at doses of 1 and 3 mg/kg significantly inhibited the consolidation of methamphetamine CPP.

Only high-dose rimonabant (3 mg/kg) disrupted the retrieval and reconsolidation of methamphetamine CPP.

Rimonabant had no effect on methamphetamine CPP in the absence of methamphetamine CPP reactivation.

CONCLUSIONS: Our findings suggest that cannabinoid CB1 receptors play a major role in methamphetamine reward memory, and cannabinoid CB1 receptor antagonists may be a potential pharmacotherapy to manage relapse associated with drug-reward-related memory.

[MeSH-major] Central Nervous System Stimulants / pharmacology. Memory / drug effects. Methamphetamine / pharmacology. Piperidines / pharmacology. Pyrazoles / pharmacology. Receptor, Cannabinoid, CB1 / antagonists & inhibitors

[MeSH-minor] Animals. Dose-Response Relationship, Drug. Male. Mice. Reward

MedlinePlus Health Information. consumer health - Memory.

MedlinePlus Health Information. consumer health - Methamphetamine.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neurobiol Learn Mem. 2008 Jul;90(1):1-9 [18342551.001]

[Cites] Drug Alcohol Rev. 2008 May;27(3):236-42 [18368604.001]

[Cites] Addiction. 1996 Jul;91(7):921-49; discussion 951-65 [8688822.001]

[Cites] Learn Mem. 2006 May-Jun;13(3):316-21 [16705137.001]

[Cites] Eur J Neurosci. 2007 Apr;25(7):2191-200 [17419755.001]

[Cites] Annu Rev Neurosci. 2007;30:123-52 [17417939.001]

[Cites] Neuropharmacology. 2002 Oct;43(5):857-67 [12384171.001]

[Cites] Eur J Neurosci. 2004 Oct;20(7):1849-57 [15380006.001]

[Cites] Acta Pharmacol Sin. 2007 Oct;28(10):1505-18 [17883935.001]

[Cites] Nat Med. 2001 Oct;7(10 ):1151-4 [11590440.001]

[Cites] J Neurosci. 2008 May 21;28(21):5602-10 [18495894.001]

[Cites] Nature. 1993 Sep 2;365(6441):61-5 [7689702.001]

[Cites] Drug Alcohol Rev. 2008 May;27(3):253-62 [18368606.001]

[Cites] Neuroscience. 1998 Mar;83(2):393-411 [9460749.001]

[Cites] Psychopharmacology (Berl). 2006 Mar;185(1):19-28 [16374599.001]

[Cites] Dialogues Clin Neurosci. 2007;9(4):389-97 [18286799.001]

[Cites] Science. 2002 Apr 26;296(5568):678-82 [11976437.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2932-7 [16473939.001]

[Cites] Am J Addict. 2001 Summer;10(3):201-17 [11579619.001]

[Cites] J Neurosci. 2008 Dec 3;28(49):13248-57 [19052216.001]

[Cites] Brain Res. 2006 Feb 23;1075(1):60-7 [16464439.001]

[Cites] Trends Neurosci. 2003 Feb;26(2):65-72 [12536129.001]

[Cites] Ann N Y Acad Sci. 2004 Oct;1025:515-27 [15542757.001]

[Cites] Neurosci Lett. 2005 Jun 3;380(3):270-5 [15862900.001]

[Cites] J Psychopharmacol. 2002 Jun;16(2):139-43 [12095072.001]

[Cites] Drug Alcohol Rev. 2008 May;27(3):243-52 [18368605.001]

[Cites] Neuropsychopharmacology. 2004 Aug;29(8):1470-8 [15085091.001]

[Cites] Behav Brain Res. 2007 Mar 12;178(1):146-53 [17239969.001]

[Cites] Neurobiol Learn Mem. 2007 Jan;87(1):93-100 [16905344.001]

[Cites] Learn Mem. 2008 May 05;15(5):304-14 [18463174.001]

[Cites] J Neurochem. 2007 Dec;103(6):2505-17 [17953657.001]

[Cites] Nature. 2005 Sep 22;437(7058):556-9 [16100511.001]

[Cites] Drug Alcohol Rev. 2008 May;27(3):229-35 [18368603.001]

[Cites] Psychopharmacology (Berl). 2007 Apr;191(2):223-31 [17211653.001]

[Cites] Neuroreport. 2007 Jul 16;18(11):1153-6 [17589317.001]

[Cites] Hippocampus. 2001;11(1):8-17 [11261775.001]

[Cites] Learn Mem. 2006 Jul-Aug;13(4):426-30 [16882859.001]

[Cites] Eur J Pharmacol. 2008 Jul 28;589(1-3):122-6 [18534572.001]

[Cites] Alcohol Clin Exp Res. 2007 Dec;31(12):2001-5 [17949470.001]

[Cites] Am J Psychiatry. 2005 Aug;162(8):1414-22 [16055762.001]

[Cites] Drug Alcohol Rev. 2008 Mar;27(2):185-9 [18264880.001]

[Cites] Behav Pharmacol. 2005 Sep;16(5-6):395-404 [16148444.001]

[Cites] Eur J Pharmacol. 2003 Sep 23;477(3):213-7 [14522359.001]

[Cites] J Neurosci. 2001 Dec 1;21(23 ):9506-18 [11717385.001]

[Cites] Prog Neurobiol. 1999 Jul;58(4):315-48 [10368032.001]

[Cites] Neurobiol Learn Mem. 2005 Mar;83(2):119-24 [15721795.001]

[Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):396-406 [15925401.001]

[Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):875-83 [15525797.001]

[Cites] Alcohol Alcohol. 2005 Jan-Feb;40(1):46-53 [15582988.001]

[Cites] Neurosci Biobehav Rev. 2004 Jan;27(8):827-39 [15019432.001]

[Cites] Trends Pharmacol Sci. 1994 Oct;15(10):374-9 [7809953.001]

[Cites] Trends Pharmacol Sci. 2005 Aug;26(8):420-6 [15992935.001]

[Cites] Jpn J Pharmacol. 2000 Nov;84(3):229-36 [11138722.001]

[Cites] Neuron. 2005 Sep 15;47(6):873-84 [16157281.001]

[Cites] Nat Rev Neurosci. 2008 Mar;9(3):182-94 [18270514.001]

[Cites] J Neurosci. 1995 Mar;15(3 Pt 2):2301-11 [7891168.001]

[Cites] J Physiol Biochem. 2000 Mar;56(1):17-24 [10879677.001]

[Cites] Neuroreport. 2006 Sep 18;17(13):1443-7 [16932155.001]

[Cites] Nature. 1990 Aug 9;346(6284):561-4 [2165569.001]

[Cites] J Neurosci. 2006 Aug 16;26(33):8531-6 [16914679.001]

[Cites] Eur J Neurosci. 2007 Jun;25(11):3417-21 [17553010.001]

[Cites] Acta Pharmacol Sin. 2006 Feb;27(2):140-4 [16412261.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11580-4 [17592122.001]

[Cites] Eur J Pharmacol. 2004 Sep 13;498(1-3):119-23 [15363985.001]

[Cites] Psychopharmacology (Berl). 2007 Dec;195(2):193-201 [17661018.001]

[Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):387-95 [15935455.001]

[Cites] Neuropharmacology. 2004;47 Suppl 1:33-46 [15464124.001]

[Cites] Annu Rev Neurosci. 2006;29:565-98 [16776597.001]

[Cites] Neurocase. 2001;7(5):357-82 [11744778.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8 [12538878.001]

[Cites] Neurobiol Learn Mem. 2008 Sep;90(2):374-81 [18524639.001]

[Cites] Trends Neurosci. 2006 Dec;29(12):695-703 [17084911.001]

[Cites] Trends Neurosci. 1990 Oct;13(10):420-3 [1700516.001]

[Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):263-84 [15936806.001]

(PMID = 19148622.001).

[ISSN] 1432-2072

[Journal-full-title] Psychopharmacology

[ISO-abbreviation] Psychopharmacology (Berl.)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 44RAL3456C / Methamphetamine; RML78EN3XE / rimonabant

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Choroid plexus tumors: a review of 28-year experience.

The aims of the study were to review the patients with choroid plexus tumor (CPT) treated in Slovenia between 1972-1999, to calculate the incidence of CPTs, and to evaluate treatment results in respect to tumor histology and mode of therapy.

Twelve patients (7 females, 5 males), 0.8-43 years old (median 6.1 years; <15 years: 10/12,83%) with CPT, representing 0.36% of all intracranial tumors registered during the period under study, were identified.

There were eight papillomas (CPPs) and four carcinomas (CPCs) with no difference in age distribution between the groups.

Of seven patients with gross tumor resection in CPP group, one patient died of postoperative meningitis and one had local recurrence 1.6 years after surgery; the latter is disease-free 17.9 years after re-operation.

In the CPC-group, only the patient who received adjuvant BEP chemotherapy and craniospinal irradiation following incomplete surgery is alive with no signs of disease after 6.5 years.

Ten-year disease-specific survival for all CPTs and for CPP subgroup was 73% and 100%, respectively.

In Slovenia, CPTs represent 0.36% of intracranial tumors.

In CPPs, the treatment of choice is surgery alone.

For CPCs, adjuvant multiagent chemotherapy and craniospinal radiotherapy following surgery should be considered.

[MeSH-major] Choroid Plexus Neoplasms / epidemiology

[MeSH-minor] Adolescent. Adult. Brain Neoplasms / diagnosis. Brain Neoplasms / epidemiology. Brain Neoplasms / therapy. Carcinoma / diagnosis. Carcinoma / epidemiology. Carcinoma / therapy. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Papilloma, Choroid Plexus / diagnosis. Papilloma, Choroid Plexus / epidemiology. Papilloma, Choroid Plexus / therapy. Recurrence. Time Factors. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15254663.001).

[ISSN] 0028-2685

[Journal-full-title] Neoplasma

[ISO-abbreviation] Neoplasma

[Language] eng

[Publication-type] Journal Article

[Publication-country] Slovakia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats.

Drug addiction is a chronic disorder characterized by a relatively high rate of relapse even after long period of abstinence.

In the present study, we used the conditioned place preference (CPP) paradigm to investigate the establishment, extinction, reinstatement and cross-reinstatement of nicotine-induced place conditioning in rats.

Nicotine produced a place preference to the initially less-preferred compartment paired with its injections during conditioning (0.5mg/kg, i.p., three drug sessions).

Once established, nicotine CPP was extinguished by repeated testing.

Following this extinction phase, the reinstatement of CPP was investigated.

These priming injections of both drugs induced a marked preference for the compartment previously paired with nicotine.

Furthermore, the objective of the present study was to evaluate the efficacy of CB1 cannabinoid receptor antagonist rimonabant (0.5, 1 and 2mg/kg, i.p.) in blocking the reinstatement of nicotine-induced CPP provoked by nicotine and morphine.

It was shown that rimonabant attenuated the reinstatement of nicotine-conditioned response induced by both drugs.

The outcome of our studies may suggest that CB1 receptor antagonists may become a promising target for effective pharmacotherapy of tobacco addiction and polydrug abuse.

[MeSH-major] Central Nervous System Agents / administration & dosage. Conditioning, Classical / drug effects. Morphine / administration & dosage. Nicotine / administration & dosage. Nicotinic Agonists / administration & dosage. Piperidines / administration & dosage. Pyrazoles / administration & dosage

[MeSH-minor] Analysis of Variance. Animals. Extinction, Psychological. Male. Random Allocation. Rats. Rats, Wistar. Receptor, Cannabinoid, CB1 / antagonists & inhibitors. Spatial Behavior / drug effects

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

Hazardous Substances Data Bank. NICOTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19463710.001).

[ISSN] 1872-7549

[Journal-full-title] Behavioural brain research

[ISO-abbreviation] Behav. Brain Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Central Nervous System Agents; 0 / Nicotinic Agonists; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 158681-13-1 / rimonabant; 6M3C89ZY6R / Nicotine; 76I7G6D29C / Morphine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.

The use of chemotherapeutic agents, such as anthracycline or trastuzumab, in oncology is limited by their cardiac toxicity.

Doxorubicin exposure decreased left ventricular developed pressure (LVDP; approximately -40% of baseline) and increased end diastolic pressure (EDP; approximately +390% of baseline) and coronary perfusion pressure (CPP; approximately +70% of baseline).

Trastuzumab exposure increased CPP and EDP (approximately +70% of baseline for the both) without affecting LVDP.

Prior rhEPO treatment significantly prevented doxorubicin-induced deleterious effects on LVDP, EDP, and VT/VF incidence. rhEPO administration also prevented trastuzumab-induced deleterious effects on CPP and EDP.

[MeSH-major] Antibodies, Monoclonal / toxicity. Antineoplastic Agents / toxicity. Doxorubicin / toxicity. Erythropoietin / therapeutic use. Heart / drug effects

[MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Blood Pressure / drug effects. In Vitro Techniques. Protective Agents / therapeutic use. Rats. Recombinant Proteins. Trastuzumab. Ventricular Fibrillation / chemically induced. Ventricular Fibrillation / prevention & control

Hazardous Substances Data Bank. Trastuzumab .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18156309.001).

[ISSN] 1535-3702

[Journal-full-title] Experimental biology and medicine (Maywood, N.J.)

[ISO-abbreviation] Exp. Biol. Med. (Maywood)

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protective Agents; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 80168379AG / Doxorubicin; P188ANX8CK / Trastuzumab

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TNF-alpha induces caspase 3 (CPP 32) dependent apoptosis in human cholangiocarcinoma cell line.

Cholangiocarcinoma (CCA), a malignant tumor derived from bile duct epithelium, occurs with a higher incidence in tropical countires especially in some areas of Southeast Asian countries such as Thailand.

This tumor is relatively resistant to chemotherapy.

In this study, molecular mechanism of killing of this tumor by TNF-alpha was investigated.

Human cholangiocarcinoma cell line (HuCCA-1) was developed and used as a model for treatment.

Activation of HuCCA-1 with TNF-alpha in the present of actinomycin D (1 microg/ml) caused death of the tumor cells.

Western blotting analysis of the cells extracted demonstrated the cleavage of poly (ADP-ribose) polymerase (PARP) within 6-8 hours following TNF-alpha treatment indicating apoptotic death.

These results indicate that apoptosis of human cholangiocarcinoma cell line as induced by TNF-alpha treatment is mediated through caspase 3.

[MeSH-major] Apoptosis / drug effects. Bile Duct Neoplasms / drug therapy. Caspases / drug effects. Cholangiocarcinoma / drug therapy. Tumor Cells, Cultured / drug effects. Tumor Necrosis Factor-alpha / therapeutic use

MedlinePlus Health Information. consumer health - Bile Duct Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 11414450.001).

[ISSN] 0125-1562

[Journal-full-title] The Southeast Asian journal of tropical medicine and public health

[ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Thailand

[Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Congenital brain tumors in a series of seven patients.

BACKGROUND: Congenital brain tumors are very rare.

METHODS: Seven congenital brain tumors were diagnosed during 5 years.

All patients presented with intracranial hypertension.

All neuroimaging studies revealed nonhomogenous tumors with cystic and solid components, except for the case with choroid plexus papilloma (CPP).

There were three teratomas, one primitive neuroectodermal tumor, one ependymoblastoma and one CPP.

One patient died due to complications of chemotherapy and another one due to tumor recurrence 1 year after surgery.

Only the patient with CPP is alive after 2 years.

CONCLUSIONS: Today, the availability of noninvasive imaging procedures such as computerized tomography scan and magnetic resonance imaging has improved the diagnosis of congenital brain tumors.

In spite of development in prenatal diagnosis, appropriate pre- and postoperative management, the mortality associated with these tumors still remains high.

CPP is accompanied by the best prognosis, whereas teratoma and primitive neuroectodermal tumors have the worst prognosis.

[MeSH-major] Brain Neoplasms / diagnosis. Fetal Diseases / diagnosis. Prenatal Diagnosis

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Fetal Health and Development.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 S. Karger AG, Basel.

(PMID = 18097184.001).

[ISSN] 1423-0305

[Journal-full-title] Pediatric neurosurgery

[ISO-abbreviation] Pediatr Neurosurg

[Language] eng

[Publication-type] Case Reports; Comparative Study; Journal Article

[Publication-country] Switzerland

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

MATERIALS AND METHODS: The female Sprague-Dawley rats were divided into intact normal (N), central precocious puberty (CPP) model (M), vehicle without CPP (V), CPP model exposed to herbal mixture (HM) and CPP model exposed to saline (S) groups.

At postnatal day 5, a single subcutaneous injection of 300 microg of danazol was administered to induce CPP model rats.

RESULTS: The day of vaginal opening and establishment of two regular estrous cycles were delayed in the HM group compared with M and S groups (P<0.05, respectively).

CONCLUSION: These results indicate that the kisspeptin signaling pathway might be involved in the effect of herbal mixture treatment on CPP.

[MeSH-major] Disease Models, Animal. Drugs, Chinese Herbal / therapeutic use. Hypothalamus / drug effects. Hypothalamus / metabolism. Proteins / metabolism. Puberty, Precocious / drug therapy

[MeSH-minor] Animals. Down-Regulation / drug effects. Down-Regulation / physiology. Female. Kisspeptins. Ovary / drug effects. Ovary / physiology. Rats. Rats, Sprague-Dawley. Up-Regulation / drug effects. Up-Regulation / physiology. Uterus / drug effects. Uterus / physiology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

(PMID = 19931369.001).

[ISSN] 1872-7573

[Journal-full-title] Journal of ethnopharmacology

[ISO-abbreviation] J Ethnopharmacol

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Kiss1 protein, rat; 0 / Kisspeptins; 0 / Proteins; 0 / nourishing Yin-removing Fire

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We aimed to investigate if the increased propensity of A2A(-/-) mice to consume ethanol is associated with an altered sensitivity in the motivational properties of ethanol in the conditioned place preference (CPP) and conditioned taste aversion (CTA) paradigms and with an altered development of sensitization to the locomotor effects of ethanol.

Our results show that A2A(-/-) mice produced on a CD1 background displayed a reduced ethanol-induced CPP and an increased sensitivity to the anxiolytic and locomotorstimulant effects of ethanol, but they did not show alteration in ethanol-induced CTA and locomotor sensitization.

Ethanol-induced CPP, ethanol consumption and the locomotor effects of ethanol were also tested in A2A(-/-) mice produced on a C57BL/6J background.

Our results emphasized the importance of the genetic background because alteration in ethanol consumption and preference, ethanol-induced CPP and locomotor-stimulant effects were not found in knockout mice produced on the alcohol-preferring C57BL/6J genetic background.

In conclusion, A2AR deficiency in mice generated on a CD1 background leads to high ethanol consumption that is associated with an increased sensitivity to the locomotor-stimulant/anxiolytic effects of ethanol and a decrease in ethanol-induced CPP.

[MeSH-major] Adenosine / metabolism. Alcohol-Induced Disorders, Nervous System / genetics. Brain / drug effects. Ethanol / pharmacology. Receptor, Adenosine A2A / drug effects

[MeSH-minor] Animals. Anti-Anxiety Agents / pharmacology. Anxiety / drug therapy. Anxiety / genetics. Anxiety / metabolism. Behavior, Animal / drug effects. Behavior, Animal / physiology. Central Nervous System Depressants / pharmacology. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Disease Models, Animal. Drug Resistance / drug effects. Drug Resistance / genetics. Genotype. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Motivation. Motor Activity / drug effects. Motor Activity / physiology. Species Specificity

Hazardous Substances Data Bank. Adenosine .

Hazardous Substances Data Bank. ETHANOL .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19097273.001).

[ISSN] 1601-183X

[Journal-full-title] Genes, brain, and behavior

[ISO-abbreviation] Genes Brain Behav.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Central Nervous System Depressants; 0 / Receptor, Adenosine A2A; 3K9958V90M / Ethanol; K72T3FS567 / Adenosine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Temperature disturbances in traumatic brain injury: relationship to secondary insults, barbiturate treatment and outcome.

OBJECTIVES: To describe the occurrence of spontaneous hyper- and hypothermia in patients with traumatic brain injury using a computerized data collecting system, to show how temperature correlates with other secondary insults, to describe how temperature affects outcome and to show how barbiturate treatment influences those analyses.

METHODS: Patients with > or = 54 hours of valid monitoring within the first 120 hours after trauma (one value/min) for temperature, intracranial pressure, cerebral perfusion pressure, systolic blood pressure, mean blood pressure and heart rate were included.

Hyperthermia correlated with occurrence of high blood pressure and high CPP.

Barbiturate treatment also confounded analyses regarding temperature and other secondary insults.

DISCUSSION: Patients with hyperthermia, hypertension, high CPP and tachycardia may suffer from a hyperdynamic state.

Barbiturate treatment confounds several analyses which have not been shown before.

[MeSH-major] Anesthetics, Intravenous / therapeutic use. Barbiturates / therapeutic use. Body Temperature / physiology. Brain Injuries / drug therapy. Brain Injuries / physiopathology

[MeSH-minor] Adolescent. Adult. Aged. Blood Pressure / drug effects. Blood Pressure / physiology. Female. Glasgow Outcome Scale. Heart Rate / drug effects. Heart Rate / physiology. Humans. Intracranial Pressure / drug effects. Intracranial Pressure / physiology. Male. Middle Aged. Retrospective Studies. Severity of Illness Index. Treatment Outcome. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19079982.001).

[ISSN] 0161-6412

[Journal-full-title] Neurological research

[ISO-abbreviation] Neurol. Res.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Barbiturates; WQ92Y2793G / barbituric acid

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

One week after weaning, the dams (n=7 per group) underwent a fully unbiased conditioned place preference (CPP) procedure to 1 mg/kg subcutaneous morphine.

CPP responses after each conditioning cycle were recorded.

Rates of acquisition and asymptotic levels of CPP were comparable in all groups; however, an inverse relationship between litter size and magnitude of morphine CPP was revealed.

Although these initial data indicate no differential sensitivity to the rewarding effects of low-dose morphine produced by the stress of litter separation, this assessment of litter size and drug-induced place conditioning in post-weaning litter-separated dams is the first of its kind.

Potential effects of other doses, drugs of abuse and post-partum manipulations remain to be evaluated within this emerging etiological model.

[MeSH-major] Body Size / drug effects. Maternal Deprivation. Morphine / administration & dosage. Narcotics / administration & dosage. Reward. Stress, Psychological / drug therapy

[MeSH-minor] Analysis of Variance. Animals. Animals, Newborn. Behavior, Animal / drug effects. Conditioning, Operant / drug effects. Female. In Vitro Techniques. Pregnancy. Rats

MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.

MedlinePlus Health Information. consumer health - Stress.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17182163.001).

[ISSN] 0278-5846

[Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry

[ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Narcotics; 76I7G6D29C / Morphine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The effects of morphine, 1-aminocyclobutane-cis-1,3-dicarboxylic (ACBD; NMDA agonist) and 3-((R)2-carboxypiperazin-4-yl)-propyl-l-phosphoric acid (CPP; NMDA antagonist) and their concurrent therapy on rat submandibular secretory function were studied.

Administration of ACBD (10 mg/kg) and CPP (10 mg/kg) alone did not influence secretion of submandibular glands.

In combination therapy, coadministration of CPP with morphine did not influence morphine-induced changes in salivary function while ABCD could restore all morphine-induced changes.

In combination treatment, ACBD prevented morphine-induced reduction of flow rate, total protein, calcium, and TGF-beta1 and reached control levels.

[MeSH-major] Morphine / adverse effects. N-Methylaspartate / agonists. Submandibular Gland / drug effects

Hazardous Substances Data Bank. MORPHINE .

Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .

Hazardous Substances Data Bank. SODIUM .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17048692.001).

[ISSN] 0236-5383

[Journal-full-title] Acta biologica Hungarica

[ISO-abbreviation] Acta. Biol. Hung.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Hungary

[Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Excitatory Amino Acid Antagonists; 0 / Glutamates; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 117488-23-0 / 2,4-methanoglutamate; 6384-92-5 / N-Methylaspartate; 76I7G6D29C / Morphine; 9NEZ333N27 / Sodium; RWP5GA015D / Potassium; SY7Q814VUP / Calcium

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In a porcine model of uncontrolled hemorrhagic shock, we evaluated the effects of fluid resuscitation versus arginine vasopressin (AVP) combined with hypertonic-hyperoncotic hydroxyethyl starch solution (HHS) on cerebral perfusion pressure (CPP) and on cerebral metabolism using intracerebral microdialysis.

Thirty minutes after drug administration, bleeding was controlled by manual compression, and colloid and crystalloid solutions were administered in both groups.

After hemodynamic decompensation, fluid resuscitation resulted in a smaller increase of CPP than did AVP/HHS (mean +/- sem; 24 +/- 5 vs 45 +/- 7 mm Hg; P < 0.01).

In conclusion, AVP/HHS proved to be superior to fluid in the initial phase of therapy with respect to CPP and cerebral oxygenation, but was comparable to fluid regarding cerebral metabolism and secondary cell damage in surviving animals.

[MeSH-major] Cerebral Cortex / metabolism. Cerebrovascular Circulation / physiology. Shock, Hemorrhagic / metabolism. Shock, Hemorrhagic / therapy

[MeSH-minor] Animals. Arginine Vasopressin / pharmacology. Carbon Dioxide / blood. Disease Models, Animal. Female. Fluid Therapy / methods. Hemodynamics. Intracranial Pressure. Liver / injuries. Male. Microdialysis. Oxygen / blood. Partial Pressure. Swine. Wounds and Injuries / blood. Wounds and Injuries / metabolism

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Carbon dioxide .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17000810.001).

[ISSN] 1526-7598

[Journal-full-title] Anesthesia and analgesia

[ISO-abbreviation] Anesth. Analg.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 113-79-1 / Arginine Vasopressin; 142M471B3J / Carbon Dioxide; S88TT14065 / Oxygen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The authors investigated the effect of nimodipine on brain tissue PO2.

METHODS: Patients in whom Hunt and Hess Grade IV or V SAH had occurred who underwent aneurysm occlusion and had stable blood pressure were prospectively evaluated using continuous brain tissue PO2 monitoring.

Data were obtained from 11 patients and measurements of brain tissue PO2, intracranial pressure (ICP), mean arterial blood pressure (MABP), and cerebral perfusion pressure (CPP) were recorded every 15 minutes.

Nimodipine resulted in a significant reduction in brain tissue PO2 in seven (64%) of 11 patients.

The baseline MABP and CPP were 90+/-20 and 84+/-19 mm Hg, respectively.

The greatest reduction in brain tissue PO2 occurred 15 minutes after administration, when the mean pressure was 26.9+/-7.7 mm Hg (p < 0.05).

In the seven patients in whom brain tissue PO2 decreased, other physiological variables such as arterial saturation, end-tidal CO2, heart rate, MABP, ICP, and CPP did not demonstrate any association with the nimodipine-induced reduction in PO2.

In four patients PO2 remained stable and none of these patients had a significant increase in brain tissue PO2.

CONCLUSIONS: Although nimodipine use is associated with improved outcome following SAH, in some patients it can temporarily reduce brain tissue PO2.

[MeSH-major] Calcium Channel Blockers / pharmacology. Intracranial Aneurysm / complications. Intracranial Aneurysm / surgery. Nimodipine / pharmacology. Oxygen / analysis. Subarachnoid Hemorrhage / drug therapy

[MeSH-minor] Aged. Brain / blood supply. Female. Humans. Intracranial Pressure. Male. Middle Aged

MedlinePlus Health Information. consumer health - Brain Aneurysm.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15481712.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Calcium Channel Blockers; 57WA9QZ5WH / Nimodipine; S88TT14065 / Oxygen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial.

Chronic post-thoracotomy pain (CPP) is associated with surgical intercostal nerve injury.

Like other forms of neuropathic pain, there is no ideal treatment.

The present study investigated the efficacy of NTG combined with the nonsteroidal anti-inflammatory drug etodolac for the treatment of CPP.

NTG, 5 mg/day, was added to the treatment.

A significant reduction in VAS was observed on day 14 of treatment (from 66.7 +/- 11 to 42.1 +/- 5, P< 0.05).

We conclude that NTG added to etodolac appears to be effective for the treatment of CPP, with minimal side effects.

[MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Etodolac / administration & dosage. Nitroglycerin / administration & dosage. Pain, Postoperative / drug therapy. Thoracotomy / adverse effects. Vasodilator Agents / administration & dosage

[MeSH-minor] Administration, Cutaneous. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prospective Studies

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15038339.001).

[ISSN] 0885-3924

[Journal-full-title] Journal of pain and symptom management

[ISO-abbreviation] J Pain Symptom Manage

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Vasodilator Agents; 2M36281008 / Etodolac; G59M7S0WS3 / Nitroglycerin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Orphanin FQ/nociceptin (NOC) has been reported to regulate dopaminergic neurotransmission in rewarding pathway, and to suppress the development of conditioned place preference (CPP) induced by certain addictive drugs.

In this study, we investigated the effect of NOC on CPP induced by repeated administration of methamphetamine (MAP) in rats.

Repeated administration of MAP (1 mg/kg, i.p.) induced substantial CPP.

MAP-induced CPP was completely suppressed by NOC (10 nmol, i.c.v.).

), an antagonist of the NOC receptor, antagonized the suppressive effect of NOC on MAP-induced CPP.

These results suggest that NOC blocks MAP-induced CPP by activation of the NOC receptor.

[MeSH-major] Conditioning (Psychology) / drug effects. Methamphetamine / antagonists & inhibitors. Methamphetamine / pharmacology. Opioid Peptides / pharmacology

[MeSH-minor] Animals. Behavior, Addictive / drug therapy. Behavior, Addictive / psychology. Male. Rats. Rats, Sprague-Dawley

MedlinePlus Health Information. consumer health - Methamphetamine.

Hazardous Substances Data Bank. d-METHAMPHETAMINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 14663196.001).

[ISSN] 0959-4965

[Journal-full-title] Neuroreport

[ISO-abbreviation] Neuroreport

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Opioid Peptides; 0 / nociceptin; 44RAL3456C / Methamphetamine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

1) To present an example of a medico-legal problem that developed as a result of a decision to rotate a chronic pain patient (CPP) to methadone in order to taper the CPP from oxycodone;.

METHODS: This is a case report of a CPP treated at a regional hospital pain clinic.

Methadone rotation was used in order to taper the CPP from oxycodone because of addictive disease.

RESULTS: During the rotation process, the CPP expired.

[MeSH-major] Analgesics, Opioid / adverse effects. Medication Errors / legislation & jurisprudence. Methadone / adverse effects. Opioid-Related Disorders. Pain / drug therapy. Pain Clinics / standards. Quality of Health Care / legislation & jurisprudence. Quality of Health Care / standards

[MeSH-minor] Adult. Autopsy. Chronic Disease. Decision Making. Expert Testimony. Florida. Humans. Male. Malpractice / legislation & jurisprudence. Oxycodone / adverse effects. Oxycodone / therapeutic use. Psychiatry

MedlinePlus Health Information. consumer health - Medication Errors.

MedlinePlus Health Information. consumer health - Pain.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. OXYCODONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Pain Med. 2004 Mar;5(1):109-10 [14996244.001]

[CommentIn] Pain Med. 2003 Jun;4(2):202-5 [12873270.001]

(PMID = 12873269.001).

[ISSN] 1526-2375

[Journal-full-title] Pain medicine (Malden, Mass.)

[ISO-abbreviation] Pain Med

[Language] eng

[Publication-type] Case Reports; Journal Article; Legal Cases

[Publication-country] United States

[Chemical-registry-number] 0 / Analgesics, Opioid; CD35PMG570 / Oxycodone; UC6VBE7V1Z / Methadone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome.

PURPOSE: To describe the clinical manifestations of classic pars planitis (CPP) in Mexican patients.

We report here the most frequent complications, medical and surgical treatment, and visual prognosis.

MATERIAL AND METHODS: A retrospective, descriptive case series examined the clinical features, complications, and treatment (medical and surgical) of CPP patients seen at the Inflammatory Eye Disease Clinic from January 1990 to September 1999.

Periocular corticosteroids were used in 97.5% of cases, systemic corticosteroids in 68.1%, and other immunosuppressive drugs in 21.3%.

CONCLUSIONS: CPP in the Mexican population is more frequent in males and usually presents in patients less than 14 years of age.

Treatment comprises periocular and systemic corticosteroids or other immunosuppressive drugs.

[MeSH-major] Pars Planitis / complications. Pars Planitis / drug therapy. Visual Acuity

[MeSH-minor] Administration, Topical. Adolescent. Adult. Anti-Inflammatory Agents / therapeutic use. Cataract / etiology. Child. Child, Preschool. Eye Diseases / etiology. Female. Glucocorticoids. Humans. Immunosuppressive Agents / therapeutic use. Macular Edema / etiology. Male. Mexico / epidemiology. Retinal Vasculitis / etiology. Retrospective Studies. Vision Disorders / etiology. Vitreous Body / pathology

Genetic Alliance. consumer health - Pars planitis.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 12854027.001).

[ISSN] 0927-3948

[Journal-full-title] Ocular immunology and inflammation

[ISO-abbreviation] Ocul. Immunol. Inflamm.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 0 / Immunosuppressive Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats.

Studies aimed at the pharmacological characterization of the receptor, which mediates the effect, have shown that the C-terminal 13 amino acid sequence is crucial for activity and that the selective NOP receptor antagonist [Nphe(1)]N/OFQ(1-13)NH(2) blocks the effect of N/OFQ on ethanol drinking.

In place conditioning studies, N/OFQ abolishes the conditioned place preference (CPP) induced by ethanol in msP rats, or by morphine in nonselected Wistar rats; these findings suggest that N/OFQ is able to abolish the rewarding properties of ethanol and morphine.

Together, these findings suggest that N/OFQ and its receptor may represent an interesting target for pharmacological treatment of alcohol abuse.

[MeSH-minor] Animals. Association Learning / drug effects. Association Learning / physiology. Conditioning, Classical / drug effects. Conditioning, Classical / physiology. Ethanol / pharmacology. Humans. Injections, Intraventricular. Mice. Morphine / pharmacology. Morphine Dependence / physiopathology. Motivation. Rats. Social Environment. Stress, Psychological / complications. Ventral Tegmental Area / drug effects. Ventral Tegmental Area / physiopathology

MedlinePlus Health Information. consumer health - Alcohol.

MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.

Hazardous Substances Data Bank. MORPHINE .

Hazardous Substances Data Bank. ETHANOL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 12818717.001).

[ISSN] 0031-9384

[Journal-full-title] Physiology & behavior

[ISO-abbreviation] Physiol. Behav.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Alcohol Deterrents; 0 / Opioid Peptides; 0 / Peptide Fragments; 0 / Receptors, Opioid; 0 / nociceptin orphanin FQ(1-17)OH; 0 / nociceptin receptor; 3K9958V90M / Ethanol; 76I7G6D29C / Morphine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments.

PURPOSE: To evaluate an intratumoral polymer implant for sustained delivery of 5-fluorouracil (5-FU) in a mouse tumor model.

METHODS AND MATERIALS: 5-FU was incorporated into a polyanhydride-based polymer, bis(p-carboxyphenoxy)propane sebacic acid (CPP:SA) and implanted in RIF-1 mouse fibrosarcoma growing s.c.

The effectiveness of treatment was evaluated by tumor growth delay.

A second drug, cis-diamminedichloroplatinum (cis-DDP), was administered by intraperitoneal injection or by osmotic pump.

RESULTS: For drug/polymer implant alone, the tumor growth delay was proportional to the amount of drug in the implant.

The 5-FU polymer implant was most effective when combined with cis-DDP or with acute or fractionated radiation, and in some cases, the effects of combined treatments were greater than additive.

CONCLUSION: Results indicate that 5-FU can be effectively delivered by polymer implant and that this mode of delivery is particularly appropriate for combined treatments.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy

[MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Cobalt Radioisotopes. Combined Modality Therapy. Iodine Radioisotopes / therapeutic use. Mice. Neoplasm Transplantation. Organoplatinum Compounds. Polymers / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Radiometry. Time Factors. Tumor Cells, Cultured

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 12459384.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobalt Radioisotopes; 0 / Iodine Radioisotopes; 0 / Organoplatinum Compounds; 0 / Polymers; 0 / Radiation-Sensitizing Agents; 78022-86-3 / diammine platinum(II) dilactate; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The objective of this study was to compare mean values and reproducibility of PP obtained in the clinic (CPP), at home (HPP) and with ambulatory monitoring (APP) and to evaluate potential implications for trials aiming to assess drug effects on PP.

METHODS: A total of 393 hypertensive subjects [mean age 51.5 +/- 11.5 (SD) years, 59% men, 35% treated] measured CPP (two visits), HPP (6 days) and APP (24 h).

The reproducibility of PP was assessed using the SD of differences (SDD) between measurements in 133 untreated subjects who had repeated CPP (five visits), HPP (6 days) and APP measurements (two occasions).

RESULTS: There was no difference between mean CPP (51.0 +/- 13.3 mmHg) and HPP (50.2 +/- 11.0) whereas APP (48.8 +/- 8.4) was lower than both CPP [mean difference 2.3 +/- 10.3 mmHg; 95% confidence interval (CI), 1.2, 3.3; P < 0.01] and HPP (1.5 +/- 7.8; 95% CI, 0.7, 2.3; P < 0.01).

The SDD between repeated measurements was about 10 mmHg for CPP (one visit), 5.2 mmHg for HPP (2 days) and 4 mmHg for APP (24-h).

For a parallel comparative trial aiming to detect a difference of 3 mmHg PP in the effect of two drugs, 415 subjects would be required when using CPP, compared to 127 using HPP and 63 using APP.

CONCLUSIONS: These data suggest that although differences among mean values of CPP, HPP and APP are small, differences in their reproducibility are important and should be taken into account in the design of trials assessing drug effects on PP.

[MeSH-minor] Adult. Age Factors. Aged. Antihypertensive Agents / therapeutic use. Circadian Rhythm / drug effects. Circadian Rhythm / physiology. Female. Humans. Hypertension / diagnosis. Hypertension / drug therapy. Hypertension / physiopathology. Male. Middle Aged. Pulse. Reproducibility of Results. Statistics as Topic. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 12359977.001).

[ISSN] 0263-6352

[Journal-full-title] Journal of hypertension

[ISO-abbreviation] J. Hypertens.

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antihypertensive Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.

PARP is activated at an intermediate stage of apoptosis and is then cleaved and inactivated at a late stage by apoptotic proteases, namely caspase-3/CPP-32/Yama/apopain and caspase-7.

With regard to the increasing interest towards PARP, the aim of this review is to explain the cellular role of PARP and the advantages of modulating its activity in diverse preventive or therapeutic strategies.

[MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / physiology. Enzyme Inhibitors / pharmacology. Humans. Poly Adenosine Diphosphate Ribose / biosynthesis. Poly(ADP-ribose) Polymerase Inhibitors. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 12164482.001).

[ISSN] 1389-2010

[Journal-full-title] Current pharmaceutical biotechnology

[ISO-abbreviation] Curr Pharm Biotechnol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 26656-46-2 / Poly Adenosine Diphosphate Ribose; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases

[Number-of-references] 100

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Since the questions concerning "neuroprotective therapy" were linked to a general survey on clinical neuroanesthesia performed by the scientific neuroanesthesia working group of the DGAI, the only departments that were assessed were those which had participated in an earlier study on neuroanesthesia in 1991.

Therapy varied considerably between departments.

Following head trauma 69% of injured patients were managed with enhanced cerebral perfusion pressure (CPP) within the range of 70-90 mmHg.

If necessary, CPP increase was induced by vasopressors (exogenous supply of catecholamines in 100% of instances) and the administration of fluids (97% of instances).

The most commonly used therapeutic approaches to treat intracranial hypertension were mannitol (95% of instances), hyperventilation (91% of instances), cerebrospinal fluid drainage (89% of instances), and barbiturates (86% of instances).

Tris (hydroxymethyl)-aminomethane was administered in almost 49%, mild hypothermia in 37%, and hypertonic-hyperoncotic solutions in 28% of patients treated for an increase in intracranial pressure.

Following intracranial aneurysm surgery "triple-H" therapy was used in 74% of patients, applied as hemodilution in 94% and as hypervolemia and hypertension in 87% of instances.

It was used in 83% of patients during perioperative care and in 52% of patients during intensive care therapy.

Specific neuroprotective drugs were applied in 68% of departments, with barbiturates (38% of instances), nimodipine (23% of instances), and corticosteroids (10% of instances) as the main agents named.

These brain-protective medications were administered especially in intracranial hypertension in 30%, in intracranial aneurysms in 21%, and in subarachnoid hemorrhages subsequent to head trauma in 18% of instances described.

CONCLUSION: These findings demonstrate that the neuroprotective therapy administered in anesthesiological departments in Germany is not yet standardized, i.e., there is a wide variation.

[MeSH-minor] Blood Pressure / physiology. Cerebrovascular Circulation / drug effects. Cerebrovascular Circulation / physiology. Craniocerebral Trauma / surgery. Data Collection. Germany. Humans. Hypothermia, Induced. Intracranial Aneurysm / surgery. Intracranial Hypertension / prevention & control. Intracranial Hypertension / therapy. Neuroprotective Agents / therapeutic use. Respiration, Artificial. Surveys and Questionnaires

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 10883355.001).

[ISSN] 0003-2417

[Journal-full-title] Der Anaesthesist

[ISO-abbreviation] Anaesthesist

[Language] ger

[Publication-type] English Abstract; Journal Article

[Publication-country] GERMANY

[Chemical-registry-number] 0 / Neuroprotective Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autoimmune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence?

Very few abnormalities in endocrine function have been reported during long term gonadotropin-releasing hormone agonist (GnRHa) treatment in girls.

Most authors agree that this therapy is safe and effective.

We present an unusual outcome of long term GnRHa therapy in two girls with central precocious puberty(CPP) of idiopathic or organic origin.

They have received monthly depot injections of triptorelin acetate for a time period of 8 years.

Another girl with a hypothalamic hamartoma developed diabetes mellitus at the age of 9 years.

Both of these girls were early diagnosed for CPP, at 6 months and 8 months respectively, and given GnRHa treatment.

So far, it is not known whether these autoimmune diseases are related to the GnRHa treatment or are simply a coincidence.

However, we suggest a closer monitoring of girls with CPP who have had a long period of treatment.

[MeSH-major] Diabetes Mellitus, Type 1 / etiology. Puberty, Precocious / drug therapy. Thyroiditis, Autoimmune / etiology. Triptorelin Pamoate / therapeutic use

[MeSH-minor] Child. Female. Hamartoma / complications. Hamartoma / drug therapy. Humans. Luteolytic Agents / therapeutic use. Pituitary Diseases / complications. Pituitary Diseases / drug therapy

Genetic Alliance. consumer health - Diabetes.

Genetic Alliance. consumer health - Precocious puberty.

Genetic Alliance. consumer health - Central precocious puberty.

Genetic Alliance. consumer health - Diabetes mellitus type 1.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20583547.001).

[ISSN] 0334-018X

[Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM

[ISO-abbreviation] J. Pediatr. Endocrinol. Metab.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Luteolytic Agents; 57773-63-4 / Triptorelin Pamoate

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Benztropine (BZT) analogs, a family of high-affinity dopamine transporter ligands, are molecules that exhibit pharmacological and behavioral characteristics predictive of significant therapeutic potential in cocaine addiction.

Here, we examined in mice the effects of 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane (AHN-1055) on motor activity, conditioned place preference (CPP) and c-Fos expression in the striatum.

Interaction assays showed that cocaine's ability to stimulate locomotor activity was decreased by AHN-1055 treatment, but not by treatment with D-amphetamine.

Remarkably, the BZT analog dose-dependently blocked cocaine-induced CPP without producing CPP when given alone, and blocked in conditioned mice cocaine-stimulated early-gene activation in the nucleus accumbens and dorsomedial striatum.

These observations provide evidence that AHN-1055 does not behave as a classical psychomotor stimulant and that some of its properties, including attenuation of cocaine-induced striatal c-Fos expression, locomotor stimulation, and CPP, support its candidacy, and that of structurally related molecules, as possible pharmacotherapies in cocaine addiction.

[MeSH-major] Benztropine / analogs & derivatives. Cocaine-Related Disorders / drug therapy. Conditioning, Classical / drug effects. Dopamine Uptake Inhibitors / pharmacology. Gene Expression / drug effects. Motor Activity / drug effects

[MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Cocaine / pharmacology. Dose-Response Relationship, Drug. Male. Mice. Nomifensine / pharmacology. Proto-Oncogene Proteins c-fos / metabolism. Reward. Space Perception / drug effects. Stereotyped Behavior / drug effects

MedlinePlus Health Information. consumer health - Cocaine.

Hazardous Substances Data Bank. NOMIFENSINE .

Hazardous Substances Data Bank. COCAINE .

Hazardous Substances Data Bank. BENZTROPINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19606084.001).

[ISSN] 1740-634X

[Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

[ISO-abbreviation] Neuropsychopharmacology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Dopamine Uptake Inhibitors; 0 / N-methyl-3-(bis(4'-fluorophenyl)methoxy)tropane; 0 / Proto-Oncogene Proteins c-fos; 1LGS5JRP31 / Nomifensine; 1NHL2J4X8K / Benztropine; I5Y540LHVR / Cocaine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: Chronic pelvic pain (CPP) affects 15% of women and has a high rate of psychiatric comorbidity.

Vulvodynia, a vulvar pain syndrome that includes vulvar vestibulitis, is the most common subtype of CPP.

This study examined the efficacy of lamotrigine for the treatment of CPP using an open-label design.

STUDY DESIGN: Forty-three women with CPP were recruited from a specialty pelvic pain clinic.

Of these, 31 completed 8 weeks of active treatment.

In particular, women with vulvodynia-type CPP (N = 17) had robust reductions in pain and mood symptoms.

CONCLUSION: CPP is a heterogeneous disorder, with psychiatric comorbidity and poor treatment response.

This open-label study suggests that treatment with lamotrigine in women with the vulvodynia subtype of CPP may be helpful in addressing both the pain and mood symptoms associated with this disorder.

[MeSH-major] Analgesics / therapeutic use. Pelvic Pain / drug therapy. Pelvic Pain / psychology. Triazines / therapeutic use. Vulvar Diseases / drug therapy. Vulvar Diseases / psychology

[MeSH-minor] Adult. Aged. Anxiety / drug therapy. Anxiety / epidemiology. Comorbidity. Depression / drug therapy. Depression / epidemiology. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Pain Measurement / drug effects. Pain Measurement / psychology. Psychiatric Status Rating Scales. Treatment Outcome. Young Adult

MedlinePlus Health Information. consumer health - Pelvic Pain.

MedlinePlus Health Information. consumer health - Vulvar Disorders.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19370903.001).

[ISSN] 0024-7758

[Journal-full-title] The Journal of reproductive medicine

[ISO-abbreviation] J Reprod Med

[Language] eng

[Grant] United States / NICHD NIH HHS / HD / K23 HD053631

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Analgesics; 0 / Triazines; U3H27498KS / lamotrigine

[Other-IDs] NLM/ NIHMS580758; NLM/ PMC4676413

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tic hydantoin sigma-1 agonist: pharmacological characterization on cocaine-induced stimulant and appetitive effects.

The most active enantiomer 4, facilitated CPP acquisition but failed to substitute for cocaine.

When CPP was acquired with cocaine and then extinguished, 4 provoked reactivation of CPP.

Preliminary ADME properties are in favour of an optimal therapeutic development.

Such Tic-hydantoin compound may serve as a new effective agonist therapy in cocaine addiction.

[MeSH-major] Appetitive Behavior / drug effects. Cocaine / pharmacology. Dopamine Uptake Inhibitors / pharmacology. Hydantoins / pharmacology. Hyperkinesis / chemically induced. Receptors, sigma / agonists

[MeSH-minor] Analysis of Variance. Animals. Behavior, Animal / drug effects. Cellulose, Oxidized / pharmacology. Chromatography, High Pressure Liquid / methods. Conditioning, Operant / drug effects. Enzyme Inhibitors / pharmacology. Ethylenediamines / pharmacology. Extinction, Psychological / drug effects. Locomotion / drug effects. Male. Mice. Protein Binding / drug effects. Time Factors

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19249191.001).

[ISSN] 1873-7862

[Journal-full-title] European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

[ISO-abbreviation] Eur Neuropsychopharmacol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Dopamine Uptake Inhibitors; 0 / Enzyme Inhibitors; 0 / Ethylenediamines; 0 / Hydantoins; 0 / INTERCEED; 0 / Receptors, sigma; 138356-20-4 / BD 1047; I5Y540LHVR / Cocaine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Recently we have shown that nitrous oxide (N2O) was able to block the expression of morphine-induced conditioned place preference (CPP) in mice.

Because dopamine (DA) has also been associated with the positive place conditioning we hypothesize that exposure to N2O would be significantly associated with a modification of extracellular level of DA.

Levels of DA, in the nucleus accumbens (Nac), in awake and freely moving rats during positive place conditioning after morphine chronic treatment has been measured by microdialysis.

Expression of morphine-induced CPP was totally abolished in mice and rats exposed to N2O.

In conclusion we showed the capacity of N2O to block the expression of morphine-induced CPP in mice and in rats.

[MeSH-major] Dopamine / metabolism. Morphine Dependence / drug therapy. Nitrous Oxide / pharmacology. Nucleus Accumbens / drug effects. Reward

[MeSH-minor] Analgesics, Opioid / pharmacology. Animals. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Drug Interactions. Male. Mice. Mice, Inbred Strains. Microdialysis. Morphine / pharmacology. Rats. Rats, Sprague-Dawley. Spatial Behavior / drug effects

HAL archives ouvertes. Full text from .

Hazardous Substances Data Bank. Nitrous oxide .

Hazardous Substances Data Bank. DOPAMINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18571333.001).

[ISSN] 0306-4522

[Journal-full-title] Neuroscience

[ISO-abbreviation] Neuroscience

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine; K50XQU1029 / Nitrous Oxide; VTD58H1Z2X / Dopamine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

M1 muscarinic receptor has been shown to be involved in cognitive functions of the brain.

Conditioned place preference (CPP) paradigm involves memory for the association between environmental stimuli and the rewarding properties produced by a treatment.

Using a balanced CPP design, we studied the possible involvement of M1 muscarinic receptors on the acquisition, expression and consolidation of morphine place conditioning in male mice.

Subcutaneous administration of morphine sulphate-induced CPP in a dose-dependent manner.

Using a 6-day schedule of conditioning, it was found that dicyclomine, an M1 muscarinic antagonist, significantly reduced the time spent by mice in the morphine compartment when given immediately, but not 6h, after each conditioning session (consolidation).

It had no effect when administered 30 min before each conditioning session during CPP training period (acquisition) or 30 min before testing for place preference in the absence of morphine (expression).

It is concluded that M1 muscarinic receptors may play a time-dependent role in the consolidation of reward-related memory of morphine.

[MeSH-major] Dicyclomine / pharmacology. Learning / drug effects. Memory / drug effects. Morphine / pharmacology. Receptor, Muscarinic M1 / antagonists & inhibitors

[MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Dose-Response Relationship, Drug. Drug Interactions / physiology. Male. Mice. Morphine Dependence / drug therapy. Morphine Dependence / metabolism. Muscarinic Antagonists / pharmacology. Narcotics / pharmacology. Reward. Time Factors

MedlinePlus Health Information. consumer health - Memory.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. MORPHINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18502314.001).

[ISSN] 1873-2747

[Journal-full-title] Brain research bulletin

[ISO-abbreviation] Brain Res. Bull.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Narcotics; 0 / Receptor, Muscarinic M1; 4KV4X8IF6V / Dicyclomine; 76I7G6D29C / Morphine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.

In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years.

In the last years, relevant improvements in the treatment of CPP have been achieved.

Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety.

In the present paper, recent advances of CPP management with GnRH analogs in men are summarized.

End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men.

The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.

[MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Puberty, Precocious / drug therapy

[MeSH-minor] Adolescent. Adult. Body Height / drug effects. Body Height / physiology. Child. Dose-Response Relationship, Drug. Humans. Male. Sex Characteristics. Treatment Outcome

Genetic Alliance. consumer health - Precocious puberty.

Genetic Alliance. consumer health - Central precocious puberty.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for central precocious puberty .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18478155.001).

[ISSN] 1008-682X

[Journal-full-title] Asian journal of andrology

[ISO-abbreviation] Asian J. Androl.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] China

[Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone

[Number-of-references] 64

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The capsid domain of the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein is a critical determinant of virus assembly, and is therefore a potential target for developing drugs for AIDS therapy.

Using this structural information, we have utilized a structure-based rational design approach to stabilize the alpha-helical structure of CAI and convert it to a cell-penetrating peptide (CPP).

This proof-of-concept cell-penetrating peptide may aid validation of capsid as an anti-HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to this protein.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2000 Sep 21;407(6802):409-13 [11014200.001]

[Cites] Biophys J. 2001 Jul;81(1):586-94 [11423440.001]

[Cites] AIDS. 2001;15 Suppl 5:S13-20 [11816161.001]

[Cites] J Virol. 2002 Mar;76(6):2641-7 [11861830.001]

[Cites] J Virol. 2002 Jul;76(14):6900-8 [12072491.001]

[Cites] Virology. 2006 Apr 25;348(1):84-95 [16442581.001]

[Cites] J Virol. 2006 Jun;80(12):5716-22 [16731910.001]

[Cites] J Virol. 2006 Aug;80(16):7939-51 [16873251.001]

[Cites] PLoS Biol. 2006 Dec;4(12):e435 [17147474.001]

[Cites] J Virol. 2007 Jul;81(14):7476-90 [17507489.001]

[Cites] Antimicrob Agents Chemother. 2002 Nov;46(11):3597-605 [12384371.001]

[Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]

[Cites] J Mol Biol. 2003 Jan 24;325(4):759-72 [12507478.001]

[Cites] J Mol Biol. 2003 Apr 11;327(5):1013-20 [12662926.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11273-8 [13679575.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60 [14573704.001]

[Cites] Angew Chem Int Ed Engl. 2005 Oct 14;44(40):6525-9 [16172999.001]

[Cites] J Virol. 2004 Jan;78(2):922-9 [14694123.001]

[Cites] J Virol. 2004 Feb;78(3):1375-83 [14722292.001]

[Cites] J Virol. 2004 Mar;78(5):2545-52 [14963157.001]

[Cites] Bioorg Med Chem Lett. 2004 Mar 22;14(6):1403-6 [15006371.001]

[Cites] J Virol. 2004 Jun;78(11):5670-8 [15140964.001]

[Cites] Protein Sci. 2004 Jun;13(6):1512-23 [15152086.001]

[Cites] Biochemistry. 2004 Aug 17;43(32):10435-41 [15301542.001]

[Cites] Science. 2004 Sep 3;305(5689):1466-70 [15353804.001]

[Cites] J Gen Virol. 2004 Oct;85(Pt 10):2903-13 [15448352.001]

[Cites] Antimicrob Agents Chemother. 2004 Nov;48(11):4349-59 [15504864.001]

[Cites] J Virol. 1986 Aug;59(2):284-91 [3016298.001]

[Cites] J Exp Med. 1991 Dec 1;174(6):1557-63 [1836013.001]

[Cites] J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74 [8207412.001]

[Cites] J Virol. 1996 Aug;70(8):5106-14 [8764018.001]

[Cites] Science. 1997 Oct 31;278(5339):849-53 [9346481.001]

[Cites] Eur J Biochem. 1997 Oct 15;249(2):592-600 [9370371.001]

[Cites] Virology. 1998 Nov 10;251(1):1-15 [9813197.001]

[Cites] Biochemistry. 2004 Nov 9;43(44):13926-31 [15518540.001]

[Cites] J Biol Chem. 2005 May 6;280(18):17664-70 [15734744.001]

[Cites] Nat Struct Mol Biol. 2005 Aug;12(8):678-82 [16041386.001]

[Cites] Nat Struct Mol Biol. 2005 Aug;12(8):671-7 [16041387.001]

[Cites] Biochemistry. 2000 Sep 26;39(38):11657-66 [10995233.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3503-8 [10725407.001]

[Cites] J Virol. 2000 Apr;74(8):3859-70 [10729160.001]

[Cites] J Virol. 2004 Jan;78(2):724-32 [14694104.001]

(PMID = 18374356.001).

[ISSN] 1089-8638

[Journal-full-title] Journal of molecular biology

[ISO-abbreviation] J. Mol. Biol.

[Language] ENG

[Grant] United States / Intramural NIH HHS / / Z01 BC010778-01; United States / NIGMS NIH HHS / GM / P41 GM066354-05; United States / NIGMS NIH HHS / GM / GM-66354; United States / NIGMS NIH HHS / GM / P41 GM066354; United States / NIGMS NIH HHS / GM / P41 GM066354-01; United States / NIGMS NIH HHS / GM / GM066354-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Gene Products, gag; 0 / NYAD-1 peptide; 0 / Peptides; 0 / Peptides, Cyclic

[Other-IDs] NLM/ NIHMS76587; NLM/ PMC2695608

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Effects of hypertonic sodium chloride hydroxyethyl starch 40 injection in treatment of acute intracranial hypertension complicated by hemorrhagic shock in dogs].

OBJECTIVE: To observe the effect of hypertonic sodium chloride hydroxyethyl starch 40 injection (HSH) in treatment of acute intracranial hypertension complicated by hemorrhagic shock in dogs, and explore the mechanism of the effects of HSH.

Canine models of acute intracranial hypertension complicated by hemorrhagic shock were established by epidural balloon inflation with saline and rapid discharge of the arterial blood.

During the shock and resuscitationperiod, the intracranial pressure (ICP), mean arterial pressure (MAP) and cerebral perfusion pressure (CPP) of the dogs were monitored, and the serum sodium level and plasma osmolality were measured at 30 min, 1 h and 4 h after the resuscitation.

RESULTS: All dogs had similar MAP, CPP, and ICP before resuscitation (P>0.05).

The CPP was also significantly increased after resuscitation (P<0.01), and in HS group, CPP decreased significantly after 2 h (P<0.01), and HSH group maintained the high CPP after 4 h.

CONCLUSION: In dogs with acute intracranial hypertension and hemorrhagic shock, HSH can effectively resuscitate hemorrhagic shock and decrease ICP, and the effect is longer-lasting than that of HS.

[MeSH-major] Hydroxyethyl Starch Derivatives / therapeutic use. Intracranial Hypertension / drug therapy. Saline Solution, Hypertonic / therapeutic use. Shock, Hemorrhagic / drug therapy

[MeSH-minor] Acute Disease. Animals. Dogs. Female. Male. Plasma Substitutes / administration & dosage. Plasma Substitutes / therapeutic use. Random Allocation. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18359696.001).

[ISSN] 1673-4254

[Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University

[ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes; 0 / Saline Solution, Hypertonic

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference.

Long-lasting drug-associated memories can contribute to relapse; therefore these memories must be inactivated to enable sustainable success in addiction therapy.

As drug associations are usually acquired over several conditioning events, we assume that an effective treatment should be repeatedly applied to achieve persistent effects.

In this study, we examine whether 10 repeated memory reactivation tests followed by systemic N-methyl-D-aspartate receptor antagonist MK-801 (0.1 mg/kg) administrations can disrupt memory reconsolidation in rats, leading to a reduction of well-established amphetamine-conditioned place preference (CPP).

We found that immediate (but not 60-min delayed) administration of MK-801 after the tests reduced amphetamine-CPP expression after at least four treatments.

These effects were specific to CPP expression as no MK-801-induced change in locomotion was observed during all tests.

We discuss these results as being caused by MK-801 disrupting memory reconsolidation and we propose the applied repeated-treatment regimen as a new therapeutic research strategy to persistently disrupt drug-associated memories.

[MeSH-major] Amphetamine / pharmacology. Central Nervous System Stimulants / pharmacology. Conditioning, Operant / drug effects. Dizocilpine Maleate / pharmacology. Memory / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors

[MeSH-minor] Animals. Behavior, Animal / drug effects. Male. Motor Activity / drug effects. Rats. Rats, Sprague-Dawley

MedlinePlus Health Information. consumer health - Memory.

Hazardous Substances Data Bank. AMPHETAMINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17912055.001).

[ISSN] 0955-8810

[Journal-full-title] Behavioural pharmacology

[ISO-abbreviation] Behav Pharmacol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Receptors, N-Methyl-D-Aspartate; 6LR8C1B66Q / Dizocilpine Maleate; CK833KGX7E / Amphetamine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height.

OBJECTIVE: This study was conducted to study the role of combination therapy of growth hormone and Gonadotropin-releasing hormone (GnRH) analogues in girls with idiopathic central precocious puberty (CPP) or idiopathic short stature (ISS).

METHODS: Five girls with CPP (median age 9.1 y, pubertal stage 2-3) (3 of them previously treated with GnRH analogue (GnRHa) for 16.2 +/- 0.3 months) and 8 girls with ISS (median age 11.4 y, pubertal stage 2-3) (previously treated with GH for 10.95 +/- 1.42 months), were treated with recombinant human GH (0.33 mg/kg/week) and GnRHa (3.75 mg/28 days) for 22 months.

RESULTS: Height of girls with CPP improved from - 1.3 to - 0.2 SDS and height for BA from - 2.1 to - 0.6 SDS (P = 0.042).

CONCLUSION: Combined treatment improves height and PAH in CPP.

[MeSH-major] Body Height / drug effects. Gonadotropin-Releasing Hormone / analogs & derivatives. Growth Disorders / drug therapy. Growth Hormone / therapeutic use. Puberty, Precocious / drug therapy

[MeSH-minor] Algorithms. Bone Development / drug effects. Child. Drug Therapy, Combination. Female. Humans. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17684302.001).

[ISSN] 0019-6061

[Journal-full-title] Indian pediatrics

[ISO-abbreviation] Indian Pediatr

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-72-6 / Growth Hormone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: The present study was designed to evaluate the effects of hypertonic-hyperoncotic hydroxyethyl starch solution (HHS) combined with either norepinephrine (NE) or arginine vasopressin (AVP) on cerebral perfusion pressure (CPP) and brain metabolism after hemorrhagic shock.

After 30 minutes of therapy, bleeding was controlled by manual compression and all surviving animals were observed for 1 hour.

RESULTS: After hemodynamic decompensation, AVP resulted in a significantly higher increase of CPP (mean +/- SD; 47 +/- 19 versus 28 +/- 9 mm Hg; p < 0.01) and cerebral venous partial pressure of oxygen (66 +/- 8 versus 49 +/- 9 mm Hg; p < 0.05) compared with NE after 10 minutes of therapy.

Brain metabolism was found comparable in both groups at any time.

CONCLUSIONS: AVP was comparable to NE with respect to hemodynamics and blood gases, as well as brain metabolism in surviving animals throughout the study period.

[MeSH-major] Hydroxyethyl Starch Derivatives / therapeutic use. Norepinephrine / therapeutic use. Plasma Substitutes / therapeutic use. Resuscitation / methods. Shock, Hemorrhagic / therapy. Vasoconstrictor Agents / therapeutic use. Vasopressins / therapeutic use

[MeSH-minor] Animals. Blood Pressure / drug effects. Brain / metabolism. Cardiac Output / drug effects. Cerebrovascular Circulation / drug effects. Microdialysis. Oxygen / blood. Sus scrofa

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. VASOPRESSIN .

Hazardous Substances Data Bank. Norepinephrine .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17414341.001).

[ISSN] 0022-5282

[Journal-full-title] The Journal of trauma

[ISO-abbreviation] J Trauma

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes; 0 / Vasoconstrictor Agents; 11000-17-2 / Vasopressins; S88TT14065 / Oxygen; X4W3ENH1CV / Norepinephrine